

TITLE: On the Proportion of Patients Who Experience a Prodrome Prior to Psychosis Onset - A Systematic Review and Meta-analysis

AUTHORS: David Benrimoh^{a,b}, Viktor Dlugunovych^c, Abigail C Wright^{d,e}, Peter Phalen^f, Melissa C. Funaro^g, Maria Ferrara^{h,i}, Albert Powers^j, Scott Woods^j, Sinan Guloksuz^k, Alison R Yung^l, Vinod Srihari^j, Jai Shah^a

^aDepartment of Psychiatry, McGill University

^bDepartment of Psychiatry, Stanford University

^cHealth + Hospitals Corporation, New York City

^dCenter of Excellence for Psychosocial and Systemic Research, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA

^eHarvard Medical School, Boston, MA, USA

^fDivision of Psychiatric Services Research, University of Maryland School of Medicine

^gHarvey Cushing/John Hay Whitney Medical Library, Yale University, New Haven, CT

^hInstitute of Psychiatry, Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy

ⁱSpecialized Treatment Early in Psychosis Program (STEP), Yale School of Medicine, New Haven, CT

^jYale University School of Medicine and the Connecticut Mental Health Center, New Haven, CT, USA

^kDepartment of Psychiatry and Neuropsychology Maastricht University Medical Center

^lInstitute of Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, , Deakin University

ABSTRACT:

BACKGROUND: Preventing or delaying the onset of psychosis requires identification of those at risk for developing psychosis. For predictive purposes, the prodrome – a constellation of symptoms which may occur before the onset of psychosis – has been increasingly recognized as having utility. However, it is unclear what proportion of patients are expected to experience a prodrome or how this varies according to the definition used.

METHODS: We conducted a systematic review and meta-analysis of studies of patients with psychosis with the objective of determining the proportion of patients who experienced a prodrome prior to psychosis onset. Inclusion criteria included a consistent prodrome definition and reporting the proportion of patients who experienced a prodrome. We excluded studies of only patients with a prodrome or solely substance-induced psychosis, qualitative studies without prevalence data, conference abstracts, and case reports/case series. We searched Ovid MEDLINE, Embase (Ovid), APA PsycInfo (Ovid), Web of Science Core Collection (Clarivate), Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, APA PsycBooks (Ovid), ProQuest Dissertation & Thesis, on March 3, 2021. Studies were assessed for quality using the Critical Appraisal Checklist for Prevalence Studies. Narrative synthesis and proportion meta-analysis were used to estimate prodrome prevalence. I^2 and predictive interval were used to assess heterogeneity. Subgroup analyses were used to probe sources of heterogeneity. (PROSPERO ID: CRD42021239797).

RESULTS: Seventy-one articles were included, representing 13,774 patients. Studies varied significantly in terms of methodology and prodrome definition used. The random effects proportion meta-analysis estimate for prodrome prevalence was 78.3% (95% CI= 72.8-83.2); heterogeneity was high (I^2 97.98% [95% CI= 97.71-98.22]); and the prediction interval was wide (95% PI= 0.411-0.936). There were no meaningful differences in prevalence between grouped prodrome definitions, and subgroup analyses failed to reveal a consistent source of heterogeneity.

CONCLUSIONS: This is the first meta-analysis on the prevalence of a prodrome prior to the onset of first episode psychosis. The majority of patients (78.3%) were found to experience a prodrome prior to psychosis onset. However, findings are highly heterogeneous across study and no definitive source of heterogeneity was found. As most studies were retrospective in nature,

recall bias likely affects these results. While the large majority of patients with psychosis experience a prodrome in some form, it is unclear if the remainder of patients experience no prodrome, or if ascertainment methods employed in the studies were not sensitive to their experiences. Given widespread investment in indicated prevention of psychosis through prospective identification and intervention during the prodrome, a resolution of this question as well as a consensus definition of the prodrome is much needed in order to effectively direct services, and may be accomplished through novel, densely sampled prospective cohort studies.

INTRODUCTION:

Schizophrenia spectrum psychotic disorders affect close to 1% of the population globally and are significant drivers of disability and healthcare costs (Kessler et al., 2005; Wu et al., 2006; Desai et al., 2013; Saha et al., 2005; Moreno-Küstner et al., 2018). With a view to improving prognostics and early intervention, there has long been an interest in characterizing the onset and early course of psychosis – including risk, premorbid, and sub-threshold periods (Hafner et al., 2003). Initial investigations centering on patients who had already developed psychosis were focused on examinations of the pre-psychotic period known as the *prodrome*, which involved collection of retrospective data. In a seminal study by Hafner et al. (1999), the prodrome was described as a period of symptoms (including, but not limited to, changes in affect, cognition, and social behavior) that was contiguous with the onset of psychosis: as such, a prodrome could only be retrospectively identified (once a psychosis had occurred), and was identified present in 73% of psychotic patients. Indeed, many models of illness development indicate the number of often nonspecific symptoms, negative symptoms, so-called “basic symptoms”, and mood changes preceding the onset of positive psychotic symptoms (e.g. Gross et al., 1987; McGlashan et al., 1996; Cupo et al., 2021).

Via the early intervention movement, the opportunity to prevent or delay onset of psychosis presented researchers with a need to prospectively identify individuals at risk for developing psychosis. Focusing on milder or “sub-threshold” versions of the characteristic symptoms of a full-blown disorder (IOM, 1994), prevention efforts therefore highlighted attenuated or brief intermittent psychotic symptoms such as perceptual abnormalities, subthreshold hallucinations or delusions, disorganization of speech and odd or unusual behavior (Yung et al., 2005; McGlashan et al., 2001). The resulting “clinical high-risk”(CHR; also known as the at-risk mental state [ARMS] or ultra high-risk [UHR]) state thus represents a ‘putative’ prodrome which prospectively identifies those close-in to the point of transitioning to psychosis who could then be followed longitudinally (McGorry et al., 2003).

Studies have now demonstrated that help-seeking individuals with these symptoms have an elevated risk of transition to psychosis for up to 10 years (Fusar-Poli et al., 2012; Salazar de Pablo et al., 2021a). These prospective definitions have also assisted in the development of novel service offerings - early intervention clinics, aimed at providing care to patients experiencing CHR states (Salazar de Pablo et al., 2021b). Work focusing on CHR has garnered

much excitement, demonstrating evidence of effectiveness as measured by reductions in duration of untreated psychosis, improvement of symptomatic and functional outcomes, while being cost-effective (Killackey & Yung, 2007; Devoe et al., 2020), though there is more limited evidence for reduction of rates of CHR symptoms and of transition to psychosis (Fusar-Poli et al., 2019; Davies et al., 2018; Worthington & Cannon, 2021).

Despite the success of work focusing on the CHR syndrome, emerging evidence regarding trajectories to psychosis has further textured our understanding of the role of the CHR syndrome and its relationship with the prodrome. First, it is now clear that the majority of CHR cases do not go on to develop psychosis, even up to 10 years following initial identification of an at-risk state (Fusar-Poli et al., 2012; Gale et al., 2013; Addington et al., 2020). Second, despite the fact that most CHR patients do not transition to psychosis, they nonetheless have high rates of developing nonpsychotic mental disorders - suggesting that 'heterotypic' shifts across diagnostic categories are frequent in this population (Simon et al., 2001; Addington et al., 2017; though this is not always demonstrated (Lin et al., 2015; Woods et al., 2018). Third, follow-back studies have now reported that in a minority of first episode psychosis cases, no identifiable pre-onset subthreshold psychotic symptoms (representing a CHR state) could be found - even when using a broad definition of prodrome (Shah et al., 2017; Schultze-Lutter et al., 2015). Even if such cases in fact represent a rapid onset of psychosis in which the at-risk state appears only momentarily before transitioning to FEP, this reduces (for those subjects) the period during which early identification aimed at the CHR stage might be effective.

In light of increasing research and programmatic investment in the CHR phase (Brady et al., 2023), these data highlight the need to consolidate knowledge regarding the question of what proportion of patients who develop psychosis actually experience a prior prodrome and/or prior sub-threshold positive symptoms (hereinafter referred to as the prodrome). Such information would be immediately relevant for determining the upper limit of how diagnostically-bounded CHR services alone can address the population of patients who will ultimately develop psychosis, either at present or if their reach is extended (Ajnakina et al., 2019). Alternately, it could generate novel models of service design, delivery or integration to delay or prevent heterotypic trajectories to psychosis. Inconsistency in measured prodrome prevalence may also be linked to changes in how the prodrome is conceptualized and captured across different research approaches (e.g. prospective versus retrospective) and definitions (e.g. broad symptoms versus sub-threshold psychotic symptoms), and might in turn inform how such

definitions can be applied in the future across clinical and research settings. Better understanding of prodrome prevalence definition and variability across studies may also help to make progress in identifying differences in prodromal phenotypes - including the absence of a prodrome - which may reflect different underlying neurobiological mechanisms, the study of which may yield useful biomarkers.

We therefore sought to fill this gap in the literature by conducting a systematic review and meta-analysis of studies to determine what proportion of patients experience a prodrome prior to psychosis onset. In keeping with the result of Hafner et al, we hypothesized that the majority of patients- in excess of 70%- would have a variably-defined prodrome prior to psychosis onset. We also expected the definitions of prodrome to vary considerably within the literature, and for broader definitions of the prodrome (that included more symptoms) to result in higher prodrome prevalences.

METHODS:

The reporting of this systematic review and meta-analysis was guided by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement. (Page et al 2020) and was pre-registered on PROSPERO (see supplementary for details). There were no deviations from the published protocol other than the addition of proportion meta-analysis (Barker et al., 2021) as an analytic technique.

Research Question

Our main research question was: “what proportion of patients who develop psychosis experience a prodromal phase prior to psychosis onset?” Because there have been different definitions of what a prodrome *is* over time, a secondary question was “how do the variable definitions and methods of measuring the prodrome affect the proportion of patients who experience a prodrome”? With respect to prodrome definitions, there is currently no gold-standard definition of a prodrome and we had no *a priori* reason to select one definition over another. We therefore adhered to the definition articulated in each study, and sought to quantify the inconsistency of results reported in the literature.

Inclusion and Exclusion Criteria

Inclusion criteria were as follows: 1) studies of first episode or subsequent episode psychosis (both affective and non-affective were included, as well as psychosis not otherwise specified) in which the prevalence of prodromal symptoms was established (whether the *primary* aim of the study or not) or 2) studies of general population cohorts followed prospectively to determine how many people experience a prodrome and eventual psychosis. In addition, studies had to 3) be studies of populations of patients, 4) provide the proportions of people who experienced a prodrome (as defined by the study) prior to onset of psychosis, and 5) apply a consistent definition of the prodrome within the study. This definition could range from specific (e.g. meeting a threshold on a specific scale) to general (e.g. a brief description of symptoms), as long as it was consistently applied.

Exclusion criteria were as follows: 1) studies in which experiencing a prodrome was an inclusion criterion as patients who developed psychosis in these cohorts would, by definition, have had a preceding prodrome, artificially inflating the proportion to 100%. We also excluded 2) qualitative studies that did not report prevalence data as well as protocols, conference proceedings/abstracts, reviews, and case studies/case series; and 3) studies solely of patients with substance-induced psychosis (though studies with a minority of patients with drug-induced psychosis were allowed; it was generally not possible to separate these patients out in prevalence calculations). Further details regarding inclusion/exclusion criteria can be found in supplementary methods.

Search Strategy

On March 3, 2021 a comprehensive search was conducted using electronic databases: Ovid MEDLINE, Embase (Ovid), APA PsycInfo (Ovid), Web of Science Core Collection (Clarivate), Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, APA PsycBooks (Ovid), and ProQuest Dissertation & Thesis. No date or language filters were used. Unpublished studies, or “gray literature” (e.g. theses, program evaluation) was also included. All search strategies are presented in the supplementary material.

The final search retrieved a total of 12852 references, which were pooled in EndNote 20 and deduplicated by the Reference Deduplicator (Yale, 2021). This set was uploaded to the

Covidence (Covidence, 2023) platform for article selection. Four articles not identified by the search were added in on the advice of experts in the field. Three of these articles did not have appropriate keywords in the abstract and title (Varsamis et al., 1971; Huber et al., 1980; Häfner et al., 1989) and one of them was published after our search had been conducted (Ferrara et al., 2021). Given the significant amount of time required to process the articles, the decision was made not to update the search once the data extraction was complete and to defer this to an updated review in the future. A flowchart per PRISMA is presented in Figure 1.

Article Selection

Each article was screened by title and abstract by two independent reviewers (D.B., A.C.W., V.D., P.P.); conflicts were resolved by an expert in the field (J.S.). Included articles were then subject to a full text review by two independent raters (D.B., A.C.W., V.D., P.P.); conflicts were resolved by group consensus at meetings including J.S.

Translations and Requests for Missing Data


For non-English articles, native speakers of the language in question with relevant expertise were sought out to assist with extraction. Speakers of English, French, Russian, Polish, and Italian were available. When these native non-English language speakers could not be found, the DEEP-L translation service (www.deepl.com) was used to provide article translations. When this translation failed or produced an unreadable article, the paper was excluded. Where further information was deemed necessary, we attempted to contact the corresponding authors of 53 articles for data or clarifications of prodrome definition and received 19 responses.

Data Extraction

Data extraction of study and patient characteristics as well as prodrome prevalence proceeded using a standardized form (available in supplementary methods). In studies which included both participants with and without psychosis, prevalence was assessed based on the total sample with psychosis. Data was extracted by one primary reviewer and this extraction was validated by a second reviewer. Conflicts in extraction were resolved via group discussion involving (D.B., V.D., A.C.W., and J.S.).

Once extracted, data was consolidated into a final data table, a subset of which is presented as Table 1. If several articles reported on the same sample, they were presented as a single entry in Table 1 and considered as a single datapoint reflected in the PRISMA diagram (Fig. 1).

Figure 1: Prisma Diagram [High Quality version attached]



Assessment of Article Quality

Quality was assessed using the Critical Appraisal Checklist for Prevalence Studies published by the Joanna Briggs Institute (hereinafter referred to as the JBI) (Martin 2017). Because of our interest in heterogeneity, we did not exclude articles deemed to be of poor quality: instead of the JBI checklist item asking the reviewer to decide to include or exclude the article, we modified the scale by asking each reviewer to independently rate the article as being of “good”, “fair” or “poor” quality based on their overall assessment of the checklist criteria. To conservatively estimate study quality, the lower of the two reviewers’ ratings was assigned to the article.

Grouping for analyses

The primary analysis of prodrome prevalence and literature heterogeneity (I^2 and prediction interval; Higgins et al., 2003; Migliavaca et al., 2022) included all selected and extracted studies. We also report the prediction interval (the interval in which the prevalence estimate from the next hypothetical study to be added to the meta-analysis is expected to lie) for the prevalence of prodrome to supplement our estimate of heterogeneity (Spence et al., 2016; Migliavaca et al., 2022). To determine potential sources of heterogeneity in the primary analyses and to assess the impact of measurement approaches, study population selection, or methodology on prodrome prevalence, further estimates of I^2 , prediction interval and prevalence were performed on the following subgroups as secondary and exploratory analyses: only those studies rated as being “fair” or “good” on quality assessment; only those studies conducted within first episode psychosis clinics; only those studies conducted using patient interviews; only those studies deriving estimates from self report; only those studies conducted on a population or catchment area sample; only those studies conducted using chart review; studies which included solely inpatients; studies with definitions inspired by the Interview for the Retrospective Assessment of the Onset of Schizophrenia (IRAOS; a detailed symptom-based measure) (Hafner et al., 1992); studies with definitions inspired by the DSM-III (APA, 1980) (which is syndromal in nature as opposed to being focused on individual symptoms); studies including only patients with schizophrenia spectrum disorders; studies including patients with more heterogeneous diagnoses (e.g. including affective psychosis and delusional disorder and other psychotic disorders); and only those studies which used a validated prodrome scale. Subgroup analyses are recommended in proportion meta-analysis, as they can assist in the determination of sources of heterogeneity (Migliavaca et al., 2022). In cases where a study’s membership in a subgroup was unclear, it was assumed not to be part of the subgroup.

Meta-analysis

For our primary aim of determining the prevalence of prodrome prior to psychosis onset, a meta-analysis of reported proportions was conducted. We used random effects models given the expected inconsistency between studies in terms of results and methodology and present the results as a forest plot. Meta-analyses were carried out using MedCalc v20.2 (MedCalc Software Ltd.). Heterogeneity (the variation in estimates between studies, whether in primary or subgroup analyses) was assessed using the I^2 metric (Higgins et al., 2003) as well as the

prediction interval. The prediction interval, which assesses the interval within which a new point estimate would lie based on the studies in the meta-analysis, and which provides another estimate of data variability with clinical relevance (based knowledge of what would constitute clinically relevant uncertainty), was calculated using Comprehensive Meta-Analysis Version 4 (Migliavaca et al., 2022; Borenstein et. al., 2022).

Publication bias

The presence of publication bias was assessed using the Begg's test and funnel plot (Begg and Mazumdar, 1994). Given the relative lack of commercial interests in this field, we did not expect there to be significant publication bias.

Categorizing prodrome definitions

We grouped prodrome definitions into three categories as follows. The first was the “Non-specific” group, which consisted of those studies which had brief or underspecified definitions; for example one study in this category defined the prodrome as a “disturbance or deviation from the patient’s previous experience and behavior that occurs before the development of florid psychotic features” (Tan et al., 2001); these may have, but did not always, include attenuated psychotic symptoms. A further example of the “Non-specific” group would be the study by Dominguez-Martinez et al., 2017, who defined the onset of the prodrome as “the earliest clinically significant deviation from the patient’s premorbid personality... established considering the first appearance of either attenuated positive or negative symptoms”. This was judged as being non-specific because any number of symptoms could be considered as fulfilling these criteria.

The second group was the “Attenuated Psychotic Symptoms Only” or “APS Only” group; this group defined the prodrome solely on the basis of sub-threshold psychotic symptoms such as perceptual changes or the onset of bizarre thoughts (e.g. Shah et al., 2017, where the focus was on 9 expert-defined sub-threshold psychotic symptoms, and Ferrara et al., 2021 where the symptoms were defined based on the Structured Interview for Psychosis-Risk Syndromes (SIPS) assessment (Miller et al., 2002)).

The third group was the “Specified Broad” group. This group considered explicit lists of symptoms or diagnoses (as opposed to the “Non-specific” group) which were broader than (but

could nonetheless include) APS. An example of the “Specified Broad” category would be the Hafner et al., 1995 study, in which a specific instrument (the IRAOS) was used to establish the presence of a number of specified symptoms. These groups are presented in Table 2.

Further exploratory analyses were conducted to assess the impact of changing definitions over time and regions on prevalence rates and are presented in the supplementary material.

RESULTS:

Articles selected

Results of the article selection process are demonstrated in the PRISMA flow diagram (Fig. 1). The search resulted in 12,852 articles. After removal of duplicates, 7,758 studies were screened. 663 relevant studies were assessed as full texts, of which 592 were excluded, leaving 71 articles in the review. The three most common reasons for exclusion were: unclear (or missing) definition of the prodrome which did not allow us to assess what the authors meant by the prodrome; ineligible type of publication (e.g. a conference abstract); or article did not contain prodrome prevalence data. Note that a given article may have had multiple reasons for exclusion, but only one reason for exclusion, based on a structured and ordered list agreed by the extraction team, was recorded per article. After merging articles which dealt with the same samples, our final dataset for this review included 51 studies.

Included studies are described in Table 1. Twenty-one studies (41.2%) were conducted in Europe; 15 (29.4%) in North America; 9 (17.6%) in Asia; 4 (7.8%) in Oceania; and 2 (3.9%) were conducted in multiple countries. These regions are of course not homogeneous with respect to language, ethnicity, culture, medical practices, and a host of other variables, but are grouped to facilitate analysis. There were no studies from South America or Africa. The majority of studies were conducted at specialty clinics, university-affiliated sites, hospitals, or within urban areas, indicating a lack of representation from community and rural sites; this is counterbalanced by other large studies examining large population samples and primary care/community clinics.

For the 44 studies that reported detailed sex or gender data, the average percentage of a sample that was male was 64% (SD=0.13). All but 4 studies were published after 1980, the year the DSM-3 was released (APA, 1980).

With respect to quality, 30 (58.8%) studies were of “Fair” quality, 7 (13.7%) of “Good” quality, and 14 (27.5%) of “Poor” quality. Methodologically, 19 (37.3%) of studies did not use a validated prodrome scale; 41 (80.4%) of studies included some form of interview with the patient; 6 (11.8%) relied solely on chart review (one of these used administrative diagnosis data rather than the chart itself); and 3 (5.9%) relied solely on self-report (i.e. questionnaires completed by patients). Forty nine (96.1%) studies determined the presence of the prodrome in a retrospective fashion (i.e. follow-back analyses after psychosis onset, relying on patient and family recall or on documentation available from before onset). There was one clearly prospective study, Maki et al, 2014, where patients from a birth cohort were administered a prodrome screening questionnaire during one time interval and were then followed to determine whether they developed psychotic symptoms during a later time interval.

Eighteen (35.3%) of the studies were catchment-based or population-level studies. With respect to setting, 24 (47%) of studies recruited solely inpatients and 9 (17.6%) were conducted at first episode psychosis/first episode schizophrenia clinics. The most common diagnoses (Table 1) were schizophrenia and schizophrenia spectrum disorders.

Table 1: Included Studies [provided in attachment]

Prodrome prevalence

The combined sample size of the included studies was 13,774 patients with psychosis. The primary outcome of this review is an estimate of the prevalence of the prodrome prior to psychosis onset. Note that for one study (Jackson et al., 1995) the authors offered several prevalences according to varying definitions; we selected the definition that produced the highest prevalence for the purposes of the meta-analysis. The results are demonstrated in the forest plot Fig 2a and the funnel plot in Fig 2b (full weights per study are available in the supplementary results).

The random effects meta-analysis estimate of the prodrome prevalence is 78.3% (95% CI= 72.8-83.2): included studies found that 78.3% of patients with psychosis experienced a pre-

onset prodrome of one definition or another. The I^2 for this analysis is 97.98% (95% CI= 97.71-98.22), demonstrating high inconsistency. The prediction interval was wide (95% PI= 0.411-0.936). Consistent with the funnel plot, there was a low risk of publication bias on Begg's test (Kendall's Tau= 0.015; $p = 0.88$).

Figure 2a: Forest Plot for all Studies [High Quality version attached]





Fig 2b: Funnel Plot for All Studies [High Quality version attached]



Prodrome definitions

There was relatively little variation in prodrome prevalence across definition categories, contrary to our initial hypothesis. Seventeen (33.3%) of the studies fell into the “Non-specific” definition category; these studies had a mean prevalence of 76.9% (SD=20.4%). Four studies (7.8%) fell into the “APS only” definition category; these studies had a mean prevalence of 72.3% (SD=25.4%). Thirty (58.8%) studies fell into the “Specified Broad” category; these had a mean prevalence of 74.5% (SD=21.2%). We included in this latter category the study by Costello (2012) which focused on administrative data, since the authors specified that any preceding mental health diagnoses would be considered to be prodromal. Final groupings based on definition can be found in table 2.

Table 2: Prodrome definitions: studies and sample sizes [provided in attachment]

Prodrome prevalence - subgroup analyses

Given the high inconsistency present in the estimate of prodrome prevalence derived from all the studies, we conducted multiple post-hoc subgroup analyses aimed at identifying potential sources of heterogeneity. These results are presented in Table 3. No subgroups demonstrated publication bias (Begg's test p 's all > 0.05).

As can be seen when reviewing Table 3, the majority of the subgroups had point estimates close to the overall estimate of 78.3%. Nonetheless, the individual estimates from each subgroup have high heterogeneity and wide prediction intervals. More intensive data gathering methodologies (e.g. interviews, using a prodrome scale) and the use of validated instruments did tend to generate higher prodrome prevalence than studies with less intensive methodologies (e.g. chart review, self-report). Overall, studies generated similar estimates even when using different definitions and when using instruments with different approaches to determining if the prodrome had been present (e.g. the DSM-III vs. the IRAOS).

Furthermore, with the exception of self report, the degree of inconsistency within each subgroup remained extremely high in all subgroups. We note that the estimates for the two studies using the SIPS assessment were relatively close: 88.1% in Ferrara et al., 2021 and 95% in Woodberry et al., 2014, but the inconsistency within the APS group is high when including all APS-definition studies. The FEP service-only subgroup yielded an estimate close to the group average; as such, the shorter recall times theoretically afforded by focusing on FEP patients does not appreciably affect the estimate. Finally, the small self-report subgroup has both a much lower estimate of the prevalence (54.8%) as well as a much lower inconsistency (0%) compared to both the analysis including all data as well as every other subgroup; however, this inconsistency had a wide confidence interval, indicating that the I^2 estimate for this subgroup (which contains only four studies) is uncertain. Predictive intervals in the subgroups were also generally wide.

Table 3: Meta-analysis Results for Subgroups [provided in attachment]

DISCUSSION:

This is the first systematic review and meta-analysis to determine what proportion of patients experience a prodromal phase prior to onset of threshold-level psychosis. Our results confirm the results of previous work (Table 1) that a prodrome is experienced by a substantial majority

of patients who develop psychosis. Our overall estimate is a prevalence of 78.3%, though individual studies have reported prevalences as low as 22% and as high as 100% - representing high heterogeneity (I^2 97.98% [95% CI= 97.71-98.22]) and a wide prediction interval (95% PI= 0.411-0.936). There were no meaningful differences in prevalence between grouped prodrome definitions, and subgroup analyses failed to reveal a consistent source of heterogeneity. Implicit in the question of how frequently the prodrome occurs before psychosis, however, are two assumptions that deserve to be examined: first, that a variably-defined pre-psychotic period (e.g. nonspecific prodrome, CHR/ARMS state, etc...) exists in a large number of patients with psychosis; and second, that these states can be accurately and reliably identified and measured using current methodologies. Our results seem to support the first assumption (i.e. that a large proportion of patients experience a prodrome). Indeed, the observation that disparate methodologies tend to generate similar estimates might increase our confidence in the general finding that the *majority* of patients experience a prodrome. However, the possibility that even a minority (21.7%) of patients experience no prodrome raises questions about measurement approaches, the underlying concepts being appraised and captured, and implications for the structure and function of next-generation services.

Are there truly patients who do not experience a prodrome?

A clear possibility is that a sizeable minority of patients experience a rapid change from a state of relative wellness to florid psychosis, without an intermediate period of nonspecific or sub-threshold symptoms - akin to previous observations of “acute” (vs. “insidious”) onset of psychosis (McGlashan, 2008; Beiser et al., 1993; Compton et al., 2008; Ito et al., 2015; Morgan et al., 2006). This subgroup has clinical relevance because it is thought to have a better prognosis (Kanahara et al., 2013; McGlashan, 2008), suggesting potentially different neurobiological mechanisms or developmental pathways underlying both their onset of illness, and perhaps the illness itself. Identifying these differences in clinical trajectory and neurobiology may ultimately lead to improved or tailored treatments for this and other subgroups. Additionally, because these patients’ putatively rapid transition to psychosis leaves little opportunity for them to be identified by CHR or general/nonspecific early-intervention services during the prodrome, services would need to be alert to this group and have intake mechanisms geared towards rapid diagnosis, assessment and treatment. A second consideration is that this subgroup *does* in fact experience a prodrome, but simply one that is less easy to measure or that is not captured by the majority of current assessment methodologies, for example because of difficulties in

recalling prodromal symptoms (the vast majority of studies considered here relied on retrospective recall or records), or because the prodrome they experience is qualitatively different to the prodrome captured by most current methods.

In summary, it is possible that a sizeable minority of patients do not experience a recognizable prodrome, but it is at least equally plausible that all patients experience some form of prodrome that is difficult to recall, transient, or challenging to identify or measure. Clarity on which of these alternatives is the case (and, should the latter alternative be the case, on what form the prodrome (or prodromes) not reliably measured by current methods takes) would provide critical knowledge to inform the breadth of feasible targets for psychosis prevention. The importance of this question for the structure and function of mental health services is not in doubt (Shah et al., 2022; Brady et al., 2023); however, resolving it requires that the field achieve a consensus definition of the prodrome, operationalizes it in a manner that can be consistently applied, and then generates prospective data from a range of settings which can then be compiled.

Is the APS definition adequate?

There is currently a great deal of clinical and research effort aimed at determining how to best provide care for, and predict transition to psychosis amongst, patients who meet the criteria for a clinical high-risk state (Fusar-Poli et al., 2012; Addington et al., 2020). The main focus in these settings continues to be on sub-threshold psychotic symptoms, commonly defined by the type and intensity of brief or attenuated positive symptoms present (Fusar-Poli et al., 2013). It is striking, however, to note that the vast majority of the literature on the prodromes experienced by patients who actually develop psychosis do not appear to focus solely on subthreshold positive symptoms of psychosis or APS. Rather, the prodrome has frequently been appreciated as inclusive of a range of affective, negative, positive, non-specific, basic, cognitive, and other symptoms. However, given the more specific definition of the prodrome contained in APS-only studies, it is perhaps surprising that these seem to yield similar estimates of prodrome prevalence, rather than meaningfully lower estimates as one might assume due to their less expansive symptom criteria. In support of this assumption, there are indeed higher prodrome prevalences (close to 100%) when broader definitions (including symptoms beyond the APS definition) are applied to identical datasets (Shah et al, 2017, Cupo et al., 2021). Nonetheless, all three definition subgroups are within 5% of each other's estimates and lie within each other's confidence intervals. Such findings suggest that most patients who eventually develop

psychosis will at some earlier point experience APS, even if their initial symptoms are nonpsychotic ones (Shah et al., 2017).

If APS are a relatively late-stage symptom cluster, occurring after changes in mood, cognition, social function, and other prodromal symptoms (Hafner et al., 1995; Cupo et al., 2021; Solmi et al., 2021), then are APS-only definitions of prodrome sufficient? With the ultimate objective being to identify patients and intervene early in order to maximize clinical benefit, interventions relying on APS-based definitions may overlook opportunities to identify or delay the onset of psychosis. Indeed, APS-specific interventions may have relatively limited effectiveness even with respect to reducing APS symptoms or transition rates for patients at the CHR stage (Davies et al., 2018; Worthington et al., 2021). As such, while APS may be a necessary and important part of an eventual gold-standard prodrome definition, they may not be adequate, especially when taking heterotypic trajectories into account. Recent work on initiatives such as HiTOP, clinical staging, and p-factor theory (Carrión et al., 2017; Caspi et al., 2014; Kotov et al., 2017; Shah et al., 2020) have all suggested that illness development occurs in a pluripotential and transdiagnostic manner, prompting a better appreciation of the heterotypy inherent in the risk, onset and course of mental illnesses. Our findings, and our recommendations below, are consistent with this understanding of illness development and the need to develop services accordingly.

Prevalence and Heterogeneity

Because the I² is a poor measure of heterogeneity in proportion meta-analyses, the use of prediction intervals and subgroup analyses is strongly recommended (Migliavaca et al., 2022). Our prediction interval runs from 41.1% to 93.6%, demonstrating the large heterogeneity in estimates of rates of prodrome between studies in the main analysis. Per subgroup analyses, high heterogeneity (in terms of both I² and PI) persists even when attempting to group studies by the instruments used, setting, or the methodological approach. While there is some degree of variability across these subgroups (likely due in part to their substantial overlap), the differences between the estimates produced are relatively modest in comparison to the heterogeneity within each subgroup; this along with overlapping confidence intervals makes interpreting these differences challenging.

The fact that the large inconsistency between study estimates persists even when subgrouping studies suggests that the inconsistency is not easily attributable to differences in specific constructs or methodologies but may instead draw on differing conceptualizations or operationalized definitions of the prodrome as well as differing research practices. This should underscore the extent to which improved uniformity of assessment of the prodrome in practice will be critical to obtaining clarity on the question of prodrome prevalence, with corresponding implications for our mechanistic understanding of psychosis onset, treatment development, and service delivery.

Strengths and Limitations

This is, to our knowledge, the first systematic review of prodrome proportion. Strengths include the incorporation of studies in multiple languages in recognition of the many ways in which the prodrome has been operationalized globally, and the fact that we integrated various definitions of the prodrome while also disaggregating them in subgroup analyses. These subgroup analyses also examined potential sources of heterogeneity. The high I^2 values reported here are common for prevalence meta-analyses, especially with large numbers of studies, and limit our ability to interpret the I^2 . In this case, we followed the recommendation of Migliavaca et al., 2022 who suggested conducting sensitivity analyses (including subgroup analyses) and reporting prediction intervals to better examine heterogeneity.

The most significant limitation in this review is the substantial heterogeneity across studies. Despite concerted attempts via prodrome category or subgroup analyses, we were unable to identify clear explanations for this. This suggests that the estimates we have identified should be interpreted with caution, and there may be unidentified variables that account for this inconsistency. It also implies that there are meaningful differences between the ways in which different research groups carry out their work that cannot be explained by broad methodological choices, and which are in turn inherently linked to the absence of standard definition of, technique for the measurement of, or lack of consensus in conceptualizing the prodrome. The lack of complementary measures (such as validated biomarkers) which could reduce ambiguity in clinical measurement and therefore potentially improve the reliability of the results presented here, is also a challenge to overcome.

Second, our review yielded few prospective studies in which prodrome definitions could be tested with respect to their predictive validity. Instead, the vast majority of studies identified relied on retrospective definitions of the prodrome, and as such on the recall of patients or the accuracy of medical records not created with the documentation of the prodrome in mind. Despite our subgroup results suggesting that studies with theoretically shorter recall periods (FEP clinic studies) do not differ meaningfully from those with potentially longer recall periods, some degree of recall bias is likely to remain in the majority of reported proportions. Researchers may have employed differing skills or effort levels when soliciting retrospective data from patients, families, or medical records - an unmeasured but potential source of heterogeneity. While this may be a key element in the explanation of our results, it can only be accounted for in future prospective studies, as we will discuss below.

Third, we note the lack of data on prodrome prevalence from South America, Africa, and Asia (including the Middle East). Cultural differences in the experience and conceptualization of psychiatric symptoms have long been recognized, which means that the findings from this review may not reflect or be directly generalizable to these jurisdictions. It is, however, reassuring to note that there were no meaningful differences in prodrome prevalence rates by the regions we could include, which does suggest some conserved phenomenology (see the supplementary material).

Fourth, the sample considered here is majority male; while this is not inconsistent with the demographics noted in first episode programs (see Table 1), women tend to have different ages and patterns to psychosis onset (Hafner et al., 1995; Ferrara & Srihari 2020; Brand et al., 2022; Carter et al., 2022; Reicher-Rossler et al., 2018) and so future efforts may need to focus on understanding gender differences in the prodrome as well.

Fifth, we note the lack of differences in prodrome point estimates between the three prodrome definitions. Part of this may be explained by the overlap between groups, and this may limit our ability to interpret this finding. For example, the majority of studies representing the non-specific and specified broad groups would have included APS as part of their definitions. However, it is striking that the non-specific definitions produced similar estimates as those studies with well-operationalized definitions.

Finally, the primary question (and its focus on prodrome prevalence) relied on the prodrome being “absent” or “present”. This may have reduced the resolution of the data available and precluded an analysis of the prodrome as a spectrum of symptoms and severities. This was necessary, however, in order to generate a metric which could be compared between studies, given the inconsistency in definitions between studies.

Recommendations for the field

The persistent heterogeneity across our analyses leads us to recommend a concerted effort to generate both a consensus definition of the prodrome, as well as a validated and universal mechanism for measuring it. Only through a large-scale, multi-site and multi-country prospective study can it be determined what proportion of individuals who develop psychosis do experience a prior prodrome (and what form or forms this takes). A prospective design with standardized and reproducible assessment methodology can enable a comprehensive range of potential prodromal symptoms to be captured while minimizing variations in researcher efforts and practices.

In addition to standardization and reproducibility, any such study would require broadly scoped, longitudinal, and temporally dense sampling of participants over an extended period of time. While the definition of the prodrome based on symptoms alone has launched and enabled decades of productive research and the development of novel clinical infrastructures, our results suggest that revised definitions of the prodrome may need to be inclusive of additional dimensions beyond symptoms alone in order to have predictive validity, which can then be used to direct services and assist in the development of novel treatments. As such, novel techniques which can be easily implemented at scale should be used to provide augmenting measures which may be clinically meaningful (Shah et al., 2020b; Benrimoh et al., 2022). These would include computerized cognitive batteries (e.g. August et al., 2012), performance on both existing and novel computational tasks (e.g. Powers et al., 2017; Teufel et al., 2015; Kafadar et al., 2022; Vercammen et al., 2010; Benrimoh et al., 2022), and potentially digital phenotyping (Huckvale et al., 2019) and biomarkers (Veronese et al., 2021; Trovão et al., 2019; Mirzakhani et al., 2014; Fernandes et al., 2020). These extra measures may, for example, help differentiate the cognitive changes seen in a patient with depression from those indicative of an incipient

psychosis. Data from this cohort would allow different prodrome definitions to be tested and selected based on a) predictive validity and b) the capacity to differentiate patients who will develop psychosis from those who will develop other mental health conditions.

Such a study would undoubtedly require immense cost and effort, but would nonetheless be worthwhile. Almost by definition, prevention or delay of early psychosis requires an understanding of what proportion of patients experience a prodrome and the form this takes. Ninety years of research - the majority of it retrospective in nature - has been unsuccessful in this endeavor, indicating the need for a concerted and prospective attempt with prospective approaches, inclusive of but not restricted to subthreshold psychotic symptoms.

Crucially, the conduct of this study in a prospective manner as described above would enable the creation not necessarily of a single definition of a unitary 'prodrome' but rather of a staged definition (Nieman & McGorry, 2015; Shah et al., 2020a), potentially with subgroups with distinct progression trajectories (including the possibility of a subgroup with no or very short prodromal periods). This staged definition would allow for the development of screening instruments or interventions best suited (in both form and intensity) to a specific stage. As a potential example of this consistent with current conceptualizations, a two stage definition might consist of an "early" prodrome corresponding to nonspecific symptoms, and a "late" prodrome in which subthreshold psychotic symptoms have emerged (Keshavan et al., 2011). The addition of novel measurement modalities (e.g. biomarkers, computational tests) may also add to the staging model as some of these measures may change in concert with, or ideally predict, changes in stage and these may in turn contribute to both screening efforts and treatment targets in the future. Overall, having a valid definition would allow us to improve screening processes, and potentially to introduce screening at scale. It would allow us to finally determine if there are some patients who will simply not develop a prodrome, and to plan services accordingly. Most importantly, it would allow further mechanistic research on individuals in "true" prodromal states (however defined) which, in turn, could allow us to develop novel treatments that could delay- or perhaps prevent- the onset of psychosis.

CONCLUSIONS:

In this systematic review and meta-analysis, we present for the first time an estimate of the prevalence of prodrome prior to psychosis onset across nearly 90 years of research. Our

estimate of 78.3%, while comprehensive, reveals a high degree of heterogeneity which largely remained even when subgrouping studies based on definitions of prodrome or on methodologies, and which was associated with a wide predictive interval. We argue that a way forward is a large-scale, prospective, densely sampled cohort study using both rigorous symptom assessments and cognitive, behavioral, and computational batteries that could generate gold-standard prodrome definition(s). The findings of such a study would serve to focus world-wide efforts to delay or prevent the onset of psychosis.

ACKNOWLEDGEMENTS:

We would like to extend our sincere thanks to the library sciences department at Yale University for their significant contributions to the process of finding, requesting, and making available articles for this review. We would also like to thank all those authors who made a significant effort to provide us with data missing from their articles in support of this review. These included: Dr. Jackson, Dr. Riecher-Rossler, Dr. Yildizhan, Dr. Pelizza, Dr. Ehrenreich, Dr. Barrantes, Dr. Velthorst, Dr. Salvatore, Dr. Dazzan, Dr. Conus, Dr. McGorry, Dr. Skokou, Dr. Woodberry, Dr. Van Os, Dr. Sullivan, Dr. Mustonen, and Dr. Renwick.

FUNDING AND CONFLICTS OF INTEREST:

No funding was received in connection to this review. D.B. is a shareholder, founder, and employee of Aifred Health, a digital mental health company which was not involved in any way with this review and whose work is not relevant to the aims of this review. D.B. did not receive funding from Aifred Health in connection to this review.

DATA AND CODE AVAILABILITY: Analyses were carried out using commercially available software. Data required to reproduce analyses are included in Table 1 and 2.

REFERENCES:

References marked with an asterisk indicate studies included in the meta-analysis

Addington, J., Liu, L., Buchy, L., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Perkins, D. O., Seidman, L. J., Tsuang, M. T., Walker, E. F., Woods, S. W., Bearden, C. E., Mathalon, D. H., & McGlashan, T. H. (2015). North American Prodrome Longitudinal Study (NAPLS 2): The Prodromal Symptoms. *The Journal of Nervous and Mental Disease*, 203(5), 328–335. <https://doi.org/10.1097/NMD.0000000000000290>

Addington, J., Piskulic, D., Liu, L., Lockwood, J., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., McGlashan, T. H., Perkins, D. O., Seidman, L. J., Tsuang, M. T., Walker, E. F., Bearden, C. E., Mathalon, D. H., & Woods, S. W. (2017). Comorbid diagnoses for youth at clinical high risk of psychosis. *Schizophrenia Research*, 190, 90–95. <https://doi.org/10.1016/j.schres.2017.03.043>

*Addington, J., van Mastrigt, S., Hutchinson, J., & Addington, D. (2002). Pathways to care: Help seeking behaviour in first episode psychosis. *Acta Psychiatrica Scandinavica*, 106(5), 358–364. <https://doi.org/10.1034/j.1600-0447.2002.02004.x>

Ajnakina, O., David, A. S., & Murray, R. M. (2019). 'At risk mental state' clinics for psychosis - an idea whose time has come - and gone!. *Psychological Medicine*, 49(4), 529–534. <https://doi.org/10.1017/S0033291718003859>

American Psychiatric Association. (1980). *Diagnostic and statistical manual of mental disorders* (3rd ed.). Arlington, VA: Author.

August, S. M., Kiwanuka, J. N., McMahon, R. P., & Gold, J. M. (2012). The MATRICS Consensus Cognitive Battery (MCCB): Clinical and cognitive correlates. *Schizophrenia Research*, 134(1), 76–82. <https://doi.org/10.1016/j.schres.2011.10.015>

*Barajas, A., Pelaez, T., Gonzalez, O., Usall, J., Iniesta, R., Arteaga, M., Jackson, C., Banos, I., Sanchez, B., Dolz, M., Obiols, J. E., Haro, J. M., Group, G., & Ochoa, S. (2019). Predictive capacity of prodromal symptoms in first-episode psychosis of recent onset. *Early Intervention in Psychiatry*, 13, 414–424. <https://doi.org/10.1111/eip.12498>

Barker, T. H., Migliavaca, C. B., Stein, C., Colpani, V., Falavigna, M., Aromataris, E., & Munn, Z. (2021). Conducting proportional meta-analysis in different types of systematic reviews: A guide for synthesisers of evidence. *BMC Medical Research Methodology*, 21(1), 189. <https://doi.org/10.1186/s12874-021-01381-z>

*Bechdolf, A., Halve, S., Schultze-Lutter, F., & Klosterkötter, J. (1998). Selbst wahrnehmbare Vulnerabilität, Prodromalsymptome und Bewältigungsreaktionen vor schizophrenen und affektiven Episoden [Self-experienced vulnerability, prodromic symptoms and coping strategies before schizophrenic and affective episodes]. *Fortschritte der Neurologie-Psychiatrie*, 66(8), 378–386. <https://doi.org/10.1055/s-2007-995275>

Begg, C. B., & Mazumdar, M. (1994). Operating characteristics of a rank correlation test for publication bias. *Biometrics*, 50(4), 1088–1101. <https://doi.org/10.2307/2533446>

Beiser, M., Erickson, D., Fleming, J. A., & Iacono, W. G. (1993). Establishing the onset of psychotic illness. *The American Journal of Psychiatry*, 150(9), 1349–1354. <https://doi.org/10.1176/ajp.150.9.1349>

Benrimoh, D., Fisher, V., Mourgues, C., Sheldon, A. D., Smith, R., & Powers, A. R. (2022). Barriers and solutions to the adoption of clinical tools for computational psychiatry. <https://doi.org/10.48550/arXiv.2301.04570>

*Bensi, M., Armando, M., Censi, V., Aiello, D., Fortes Lindau, J., Cavaggioni, G., Birchwood, M., & Fiori Nastro, P. (2011). Segni e sintomi prodromici all'esordio psicotico. Uno studio sulla Duration of Untreated Illness (DUI) in un campione di pazienti con diagnosi di psicosi non affettiva [Early signs and symptoms before the psychotic onset. A study on the Duration of Untreated Illness (DUI) in a sample of patients with diagnosis of "non-affective psychotic disorders"]. *La Clinica Terapeutica*, 162(1), 11–18. <https://pubmed.ncbi.nlm.nih.gov/21448540/>

Borenstein, M., Hedges, L. E., Higgins, J. P. T., & Rothstein, H. R. (2022). *Comprehensive Meta-Analysis* (Version 4). [Computer software]. www.Meta-Analysis.com

Brady, L. S., Larrauri, C. A., & AMP SCZ Steering Committee. (2023). Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Developing tools to enable early intervention in the psychosis high risk state. *World Psychiatry: Official Journal of the World Psychiatric Association (WPA)*, 22(1), 42–43. <https://doi.org/10.1002/wps.21038>

Brand, B. A., de Boer, J. N., Dazzan, P., & Sommer, I. E. (2022). Towards better care for women with schizophrenia-spectrum disorders. *The Lancet. Psychiatry*, 9(4), 330–336. [https://doi.org/10.1016/S2215-0366\(21\)00383-7](https://doi.org/10.1016/S2215-0366(21)00383-7)

*Bunk, D., Eggers, C., Volberg, G., & Schebaum-Stein, T. (2003). Dimensions of premorbid disorders in childhood-onset schizophrenia (COS). *Neurology Psychiatry and Brain Research*, 10, 183–192.

Carrión, R. E., Correll, C. U., Auther, A. M., & Cornblatt, B. A. (2017). A severity-based clinical staging model for the psychosis prodrome: Longitudinal findings from the New York Recognition and Prevention Program. *Schizophrenia Bulletin*, *43*(1), 64–74.

<https://doi.org/10.1093/schbul/sbw155>

Carter, B., Wootten, J., Archie, S., Terry, A. L., & Anderson, K. K. (2022). Sex and gender differences in symptoms of early psychosis: A systematic review and meta-analysis. *Archives of Women's Mental Health*, *25*(4), 679–691.

<https://doi.org/10.1007/s00737-022-01247-3>

Caspi, A., Houts, R. M., Belsky, D. W., Goldman-Mellor, S. J., Harrington, H., Israel, S., Meier, M. H., Ramrakha, S., Shalev, I., Poulton, R., & Moffitt, T. E. (2014). The p factor: One general psychopathology factor in the structure of psychiatric disorders?. *Clinical Psychological Science: A Journal of the Association for Psychological Science*, *2*(2), 119–137.

<https://doi.org/10.1177/2167702613497473>

*Chen, E. Y. H., Dunn, E. L. W., Miao, M., Yeung, W. S., Wong, C. K., Chan, W. F., Chen, R. Y. L., Chung, K. F., & Tang, W. N. (2005). The impact of family experience on the duration of untreated psychosis (DUP) in Hong Kong. *Social Psychiatry and Psychiatric Epidemiology*, *40*, 350–356. <https://doi.org/10.1007/s00127-005-0908-z>

*Chen, Y., Farooq, S., Edwards, J., Chew-Graham, C. A., Shiers, D., Frisher, M., Hayward, R., Sumathipala, A., & Jordan, K. P. (2019). Patterns of symptoms before a diagnosis of first episode psychosis: A latent class analysis of UK primary care electronic health records. *BMC Medicine*, *17*, 227. <https://doi.org/10.1186/s12916-019-1462-y>

*Compton, M. T., Broussard, B., Ramsay, C. E., & Stewart, T. (2011). Pre-illness cannabis use and the early course of nonaffective psychotic disorders: Associations with premorbid functioning, the prodrome, and mode of onset of psychosis. *Schizophrenia Research*, *126*, 71–76. <https://doi.org/10.1016/j.schres.2010.10.005>

*Compton, M. T., Chien, V. H., Leiner, A. S., Goulding, S. M., & Weiss, P. S. (2008). Mode of onset of psychosis and family involvement in help-seeking as determinants of duration of untreated psychosis. *Social Psychiatry and Psychiatric Epidemiology: The International Journal for Research in Social and Genetic Epidemiology and Mental Health Services*, *43*(12), 975–982. <https://doi.org/10.1007/s00127-008-0397-y>

*Compton, M. T., Esterberg, M. L., Druss, B. G., Walker, E. F., & Kaslow, N. J. (2006). A descriptive study of pathways to care among hospitalized urban African American first-episode schizophrenia-spectrum patients. *Social Psychiatry and Psychiatric Epidemiology*, 41(7), 566–573. <https://doi.org/10.1007/s00127-006-0065-z>

*Compton, M. T., Goulding, S. M., & Walker, E. F. (2010). Characteristics of the retrospectively assessed prodromal period in hospitalized patients with first-episode nonaffective psychosis: Findings from a socially disadvantaged, low-income, predominantly African American population. *Journal of Clinical Psychiatry*, 71, 1279–1285. <https://doi.org/10.4088/JCP.08m04678yel>

*Compton, M. T., Kelley, M. E., Ramsay, C. E., Pringle, M., Goulding, S. M., Esterberg, M. L., Stewart, T., & Walker, E. F. (2009). Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. *American Journal of Psychiatry*, 166, 1251–1257. <https://doi.org/10.1176/appi.ajp.2009.09030311>

*Conus, P., Cotton, S., Schimmelmann, B. G., McGorry, P. D., & Lambert, M. (2007). The first-episode psychosis outcome study: Premorbid and baseline characteristics of an epidemiological cohort of 661 first-episode psychosis patients. *Early Intervention in Psychiatry*, 1, 191–200. <https://doi.org/10.1111/j.1751-7893.2007.00026.x>

*Coryell, W., & Zimmerman, M. (1988). Diagnosis and outcome in schizo-affective depression: A replication. *Journal of Affective Disorders*, 15, 21–27. [https://doi.org/10.1016/0165-0327\(88\)90005-5](https://doi.org/10.1016/0165-0327(88)90005-5)

*Costello, A. (2012). Mental health diagnoses during the year prior to schizophrenia, U.S. Armed Forces, 2001-2010. *MSMR*, 19, 10–13. <https://pubmed.ncbi.nlm.nih.gov/22452716/>

*Creel, S. M. (1988). Prodromal psychosocial behaviors in soldiers with schizophrenic and schizophreniform disorder. *Military Medicine*, 153, 146–150. <https://doi.org/10.1093/milmed/153.3.146>

*Cupo, L., McIlwaine, S. V., Daneault, J. G., Malla, A. K., Iyer, S. N., Joober, R., & Shah, J. L. (2021). Timing, distribution, and relationship between nonpsychotic and

subthreshold psychotic symptoms prior to emergence of a first episode of psychosis.

Schizophrenia Bulletin, 47(3), 604–614. <https://doi.org/10.1093/schbul/sbaa183>

Davies, C., Radua, J., Cipriani, A., Stahl, D., Provenzani, U., McGuire, P., & Fusar-Poli, P. (2018). Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: A network meta-analysis.

Frontiers in Psychiatry, 9, 187. <https://doi.org/10.3389/fpsyt.2018.00187>

*Day, R., Nielsen, J. A., Korten, A., Ernberg, G., Dube, K. C., Gebhart, J., Jablensky, A., Leon, C., Marsella, A., & Olatawura, M. (1987). Stressful life events preceding the acute onset of schizophrenia: A cross-national study from the World Health Organization.

Culture, Medicine and Psychiatry, 11(2), 123–205. <https://doi.org/10.1007/BF00122563>

Desai, P. R., Lawson, K. A., Barner, J. C., & Rascati, K. L. (2013). Estimating the direct and indirect costs for community-dwelling patients with schizophrenia. *Journal of Pharmaceutical Health Services Research*, 4(4), 187–194. doi/10.1111/jphs.12027/epdf

Devoe, D. J., Farris, M. S., Townes, P., & Addington, J. (2020). Interventions and transition in youth at risk of psychosis: A systematic review and meta-analyses. *The Journal of Clinical Psychiatry*, 81(3), 17r12053. <https://doi.org/10.4088/JCP.17r12053>

*Dominguez-Martinez, T., Cristobal-Narvaez, P., Kwapil, T. R., & Barrantes-Vidal, N. (2017). Clinical and psychosocial characterization of at-risk mental state and recent onset psychosis patients from an Early Psychosis Program in Barcelona (Spain). *Actas Espanolas de Psiquiatria*, 45, 145–156. <https://pubmed.ncbi.nlm.nih.gov/28745387/>

*Eggers, C. (1973). The course of infantile and prepubertal schizophrenia.

Monographien Aus Dem Gesamtgebiete Der Psychiatrie, 9, 250. DOI 10.1007/978-3-662-13371-2

*Eggers, C., & Bunk, D. (1997). The long-term course of childhood-onset schizophrenia: A 42-year followup. *Schizophrenia Bulletin*, 23(1), 105–117.

<https://doi.org/10.1093/schbul/23.1.105>

*Eggers, C., & Bunk, D. (2009). Frühentwicklung kindlicher schizophrenien [Early development of childhood-onset schizophrenia]. *Fortschritte der Neurologie, Psychiatrie*, 77(10), 558–567. <https://doi.org/10.1055/s-0028-1109737>

*Eggers, C., Bunk, D., & Krause, D. (2000). Schizophrenia with onset before the age of eleven: Clinical characteristics of onset and course. *Journal of Autism and Developmental Disorders*, 30(1), 29–38. <https://doi.org/10.1023/a:1005408010797>

*Emck, C., Schothorst, P. F., & Van Engeland, H. (2001). Psychosen bij jeugdigen [Early onset psychosis]. *Tijdschrift Voor Psychiatrie*, 43, 757–765. <https://research.vu.nl/en/publications/psychosen-bij-jeugdigen>

Fernandes, B. S., Karmakar, C., Tamouza, R., Tran, T., Yearwood, J., Hamdani, N., Laouamri, H., Richard, J. R., Yolken, R., Berk, M., Venkatesh, S., & Leboyer, M. (2020). Precision psychiatry with immunological and cognitive biomarkers: A multi-domain prediction for the diagnosis of bipolar disorder or schizophrenia using machine learning. *Translational Psychiatry*, 10(1), 162. <https://doi.org/10.1038/s41398-020-0836-4>

Ferrara, M., & Srihari, V. H. (2021). Early intervention for psychosis in the United States: Tailoring services to improve care for women. *Psychiatric Services (Washington, D.C.)*, 72(1), 5–6. <https://doi.org/10.1176/appi.ps.202000205>

*Ferrara, M., Guloksuz, S., Mathis, W. S., Li, F., Lin, I. H., Syed, S., Gallagher, K., Shah, J., Kline, E., Tek, C., Keshavan, M., & Srihari, V. H. (2021). First help-seeking attempt before and after psychosis onset: Measures of delay and aversive pathways to care. *Social Psychiatry and Psychiatric Epidemiology*, 56(8), 1359–1369. <https://doi.org/10.1007/s00127-021-02090-0>

Fusar-Poli, P., Bonoldi, I., Yung, A. R., Borgwardt, S., Kempton, M. J., Valmaggia, L., Barale, F., Caverzasi, E., & McGuire, P. (2012). Predicting psychosis: Meta-analysis of transition outcomes in individuals at high clinical risk. *Archives of General Psychiatry*, 69(3), 220–229. <https://doi.org/10.1001/archgenpsychiatry.2011.1472>

Fusar-Poli, P., Borgwardt, S., Bechdolf, A., Addington, J., Riecher-Rössler, A., Schultze-Lutter, F., Keshavan, M., Wood, S., Ruhrmann, S., Seidman, L. J., Valmaggia, L., Cannon, T., Velthorst, E., De Haan, L., Cornblatt, B., Bonoldi, I., Birchwood, M., McGlashan, T., Carpenter, W., McGorry, P., ... Yung, A. (2013). The psychosis high-risk state: A comprehensive state-of-the-art review. *JAMA Psychiatry*, 70(1), 107–120. <https://doi.org/10.1001/jamapsychiatry.2013.269>

Fusar-Poli, P., Davies, C., Solmi, M., Brondino, N., De Micheli, A., Kotlicka-Antczak, M., Shin, J. I., & Radua, J. (2019). Preventive treatments for psychosis: Umbrella review (just the evidence). *Frontiers in Psychiatry, 10*, 764.

<https://doi.org/10.3389/fpsy.2019.00764>

Gale, C., Glue, P., & Gallagher, S. (2013). Bayesian analysis of posttest predictive value of screening instruments for the psychosis high-risk state. *JAMA Psychiatry, 70*(8), 880–881. <https://doi.org/10.1001/jamapsychiatry.2013.1320>

*Gottlieb, B. S. (1941). Prognosis of hebephrenia; a study of onset and clinical manifestations. *Psychiatric Quarterly, 15*, 54–63. <https://doi.org/10.1007/BF01613954>

*Gourzis, P., Katrivanou, A., & Beratis, S. (2002). Symptomatology of the initial prodromal phase in schizophrenia. *Schizophrenia Bulletin, 28*(3), 415–429.

<https://doi.org/10.1093/oxfordjournals.schbul.a006950>

Gross, G., Huber, G., Klosterkötter, J., & Linz, M. *Bonner Skala für die Beurteilung von Basissymptomen* [BSABS; Bonn Scale for the Assessment of Basic Symptoms]. Berlin, Germany: Springer; 1987.

*Guloksuz, S., Pries, L. K., Ten Have, M., de Graaf, R., van Dorselaer, S., Klingenberg, B., Bak, M., Lin, B. D., van Eijk, K. R., Delespaul, P., van Amelsvoort, T., Luykx, J. J., Rutten, B. P. F., & van Os, J. (2020). Association of preceding psychosis risk states and non-psychotic mental disorders with incidence of clinical psychosis in the general population: A prospective study in the NEMESIS-2 cohort. *World Psychiatry, 19*, 199–205. <https://doi.org/10.1002/wps.20755>

*Hafner, H. (1996). When, how and with what does schizophrenia begin? *Jornal Brasileiro de Psiquiatria, 45*, 7–21.

*Hafner, H. (1998). Onset and course of the first schizophrenic episode. *Kaohsiung Journal of Medical Sciences, 14*, 413–431. <https://pubmed.ncbi.nlm.nih.gov/9739575/>

*Hafner, H. (2000). Onset and early course as determinants of the further course of schizophrenia. *Acta Psychiatrica Scandinavica, Supplementum, 407*, 44–48. <https://pubmed.ncbi.nlm.nih.gov/11261639/>

Häfner, H. (2003). Prodrome, onset and early course of schizophrenia. In R. M. Murray, P. B. Jones, E. Susser, J. van Os, & M. Cannon (Eds.), *The epidemiology of schizophrenia* (pp. 124–147). Cambridge University Press.

<https://doi.org/10.1002/9780470987353.ch8>

Häfner, H., & Nowotny, B. (1995). Epidemiology of early-onset schizophrenia. *European Archives of Psychiatry and Clinical Neuroscience*, 245(2), 80–92.

<https://doi.org/10.1007/BF02190734>

*Häfner, H., Löffler, W., Maurer, K., Hambrecht, M., & an der Heiden, W. (1999). Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. *Acta Psychiatrica Scandinavica*, 100(2), 105–118.

<https://doi.org/10.1111/j.1600-0447.1999.tb10831.x>

*Häfner, H., Maurer, K., Löffler, W., an der Heiden, W., Stein, A., Könnecke, R., & Hambrecht, M. (1999). Onset and prodromal phase as determinants of the course. *Search for the causes of schizophrenia: Vol. IV Balance of the century* (pp. 35-58). Steinkopff. DOI: 10.1007/978-3-642-47076-9_3

*Häfner, H., Nowotny, B., Löffler, W., an der Heiden, W., & Maurer, K. (1995). When and how does schizophrenia produce social deficits? *European Archives of Psychiatry and Clinical Neuroscience*, 246(1), 17–28. <https://doi.org/10.1007/BF02191811>

Häfner, H., Riecher-Rössler, A., Hambrecht, M., Maurer, K., Meissner, S., Schmidtke, A., Fätkenheuer, B., Löffler, W., & van der Heiden, W. (1992). IRAOS: An instrument for the assessment of onset and early course of schizophrenia. *Schizophrenia Research*, 6(3), 209–223. [https://doi.org/10.1016/0920-9964\(92\)90004-o](https://doi.org/10.1016/0920-9964(92)90004-o)

Häfner, H., Riecher, A., Maurer, K., Löffler, W., Munk-Jørgensen, P., & Strömgen, E. (1989). How does gender influence age at first hospitalization for schizophrenia? A transnational case register study. *Psychological Medicine*, 19(4), 903–918.

<https://doi.org/10.1017/S0033291700005626>

Higgins, J. P., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analyses. *BMJ (Clinical research ed.)*, 327(7414), 557–560.

<https://doi.org/10.1136/bmj.327.7414.557>

*Huber, G., Gross, G., & Schüttler, R. (1975). A long-term follow-up study of schizophrenia: psychiatric course of illness and prognosis. *Acta Psychiatrica Scandinavica*, 52(1), 49–57. <https://doi.org/10.1111/j.1600-0447.1975.tb00022.x>

Huber, G., Gross, G., Schüttler, R., & Linz, M. (1980). Longitudinal studies of schizophrenic patients. *Schizophrenia Bulletin*, 6(4), 592–605. <https://doi.org/10.1093/schbul/6.4.592>

Huckvale, K., Venkatesh, S., & Christensen, H. (2019). Toward clinical digital phenotyping: A timely opportunity to consider purpose, quality, and safety. *NPJ digital medicine*, 2(1), 1-11. <https://doi.org/10.1038/s41746-019-0166-1>

*Iida, J., Iwasaka, H., Hirao, F., Hashino, K., Matsumura, K., Tahara, K., Aoyama, F., Sakiyama, S., Tsujimoto, H., Kawabata, Y., & Ikawa, G. (1995). Clinical features of childhood-onset schizophrenia with obsessive-compulsive symptoms during the prodromal phase. *Psychiatry and Clinical Neurosciences*, 49(4), 201–207. <https://doi.org/10.1111/j.1440-1819.1995.tb01885.x>

Institute of Medicine (US) Committee on Prevention of Mental Disorders. (1994). In Mrazek, P. J., & Haggerty, R. J. (Eds.), *Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research*. National Academies Press (US). <https://pubmed.ncbi.nlm.nih.gov/25144015/>

Ito, S., Nemoto, T., Tsujino, N., Ohmuro, N., Matsumoto, K., Matsuoka, H., Tanaka, K., Nishiyama, S., Suzuki, M., Kinoshita, H., Ozawa, H., Fujita, H., Shimodera, S., Kishimoto, T., Matsumoto, K., Hasegawa, T., & Mizuno, M. (2015). Differential impacts of duration of untreated psychosis (DUP) on cognitive function in first-episode schizophrenia according to mode of onset. *European Psychiatry: The Journal of the Association of European Psychiatrists*, 30(8), 995–1001. <https://doi.org/10.1016/j.eurpsy.2015.08.004>

*Iyer, S. N., Boekestyn, L., Cassidy, C. M., King, S., Jooper, R., & Malla, A. K. (2008). Signs and symptoms in the pre-psychotic phase: Description and implications for diagnostic trajectories. *Psychological Medicine*, 38, 1147–1156. <https://doi.org/10.1017/S0033291708003152>

*Jackson, H. J., McGorry, P. D., Dakis, J., Harrigan, S., Henry, L., & Mihalopoulos, C. (1996). The inter-rater and test–retest reliabilities of prodromal symptoms in first-episode psychosis. *Australian and New Zealand Journal of Psychiatry*, 30(4), 498–504.

<https://doi.org/10.3109/00048679609065023>

*Jackson, H. J., McGorry, P. D., & Dudgeon, P. (1995). Prodromal symptoms of schizophrenia in first-episode psychosis: Prevalence and specificity. *Comprehensive Psychiatry*, 36(4), 241–250. [https://doi.org/10.1016/s0010-440x\(95\)90068-3](https://doi.org/10.1016/s0010-440x(95)90068-3)

Joanna Briggs Institute. (2017). Critical Appraisal Checklist for Prevalence Studies.

https://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Prevalence_Studies2017_0.pdf

Kafadar, E., Fisher, V. L., Quagan, B., Hammer, A., Jaeger, H., Mourgues, C., ... & Powers, A. R. (2022). Conditioned hallucinations and prior overweighting are state-sensitive markers of hallucination susceptibility. *Biological Psychiatry*, 92(10), 772-780.

<https://doi.org/10.1016/j.biopsych.2022.05.007>

*Kanahara, N., Yoshida, T., Oda, Y., Yamanaka, H., Moriyama, T., Hayashi, H., Shibuya, T., Nagaushi, Y., Sawa, T., Sekine, Y., Shimizu, E., Asano, M., & Iyo, M. (2013). Onset pattern and long-term prognosis in schizophrenia: 10-Year longitudinal follow-up study. *PLoS ONE [Electronic Resource]*, 8, e67273.

<https://doi.org/10.1371/journal.pone.0067273>

Keshavan, M. S., DeLisi, L. E., & Seidman, L. J. (2011). Early and broadly defined psychosis risk mental states. *Schizophrenia Research*, 126(1–3), 1–10.

<https://doi.org/10.1016/j.schres.2010.10.006>

Kessler, R. C., Birnbaum, H., Demler, O., Falloon, I. R., Gagnon, E., Guyer, M., Howes, M. J., Kendler, K. S., Shi, L., Walters, E., & Wu, E. Q. (2005). The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). *Biological psychiatry*, 58(8), 668–676.

<https://doi.org/10.1016/j.biopsych.2005.04.034>

Killackey, E., & Yung, A. R. (2007). Effectiveness of early intervention in psychosis. *Current Opinion in Psychiatry*, 20(2), 121–125.

<https://doi.org/10.1097/YCO.0b013e328017f67d>

*Kim, Y., Lee, J. Y., Yong, S. K., Jung, H. Y., & Lee, K. Y. (2009). Reliability of the Korean Nottingham Onset Schedule (K-NOS) in Korean first-episode psychosis patients. *Clinical Psychopharmacology and Neuroscience*, 7, 51–56.

<https://www.cpn.or.kr/journal/view.html?uid=69&vmd=Full>

*Kohn, D., Niedersteberg, A., Wieneke, A., Bechdorf, A., Pukrop, R., Ruhrmann, S., Schultze-Lutter, F., Maier, W., & Klosterkötter, J. (2004). Early course of illness in first episode schizophrenia with long duration of untreated illness—A comparative study.

Fortschritte Der Neurologie-Psychiatrie, 72, 88–92. DOI:[10.1055/s-2003-812509](https://doi.org/10.1055/s-2003-812509)

Kotov, R., Krueger, R. F., Watson, D., Achenbach, T. M., Althoff, R. R., Bagby, R. M., Brown, T. A., Carpenter, W. T., Caspi, A., Clark, L. A., Eaton, N. R., Forbes, M. K., Forbush, K. T., Goldberg, D., Hasin, D., Hyman, S. E., Ivanova, M. Y., Lynam, D. R., Markon, K., ... Zimmerman, M. (2017). The Hierarchical Taxonomy of Psychopathology (HiTOP): A dimensional alternative to traditional nosologies. *Journal of Abnormal Psychology*, 126(4), 454–477. <https://doi.org/10.1037/abn0000258>

Lin A, Wood SJ, Nelson B, Beavan A, McGorry P, Yung AR (2015): Outcomes of non-transitioned cases in a sample at ultra-high risk for psychosis. *American Journal of Psychiatry*. 172:249-258.

*Maki, P., Koskela, S., Murray, G. K., Nordstrom, T., Miettunen, J., Jaaskelainen, E., & Veijola, J. M. (2014). Difficulty in making contact with others and social withdrawal as early signs of psychosis in adolescents—The Northern Finland Birth Cohort 1986.

European Psychiatry: The Journal of the Association of European Psychiatrists, 29, 345–351. <https://doi.org/10.1016/j.eurpsy.2013.11.003>

*Maurer, K., Konnecke, R., Löffler, W., & Hafner, H. (1998). Some new results from the ABC-study on early course and early recognition. *Neurology Psychiatry and Brain Research*, 6, 9–18.

McGlashan T. H. (2008). Premorbid adjustment, onset types, and prognostic scaling: Still informative?. *Schizophrenia Bulletin*, 34(5), 801–805.

<https://doi.org/10.1093/schbul/sbn073>

McGlashan, T. H., & Johannessen, J. O. (1996). Early detection and intervention with schizophrenia: rationale. *Schizophrenia Bulletin*, 22(2), 201–222.

<https://doi.org/10.1093/schbul/22.2.201>

McGlashan, T. H., Miller, T. J., Woods, S. W., Hoffman, R. E., & Davidson, L. (2001). Instrument for the assessment of prodromal symptoms and states. *Early Intervention in Psychotic Disorders*, 135–149. https://link.springer.com/chapter/10.1007/978-94-010-0892-1_7

McGorry, P. D., Yung, A. R., & Phillips, L. J. (2003). The "close-in" or ultra high-risk model: A safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. *Schizophrenia Bulletin*, 29(4), 771–790.

<https://doi.org/10.1093/oxfordjournals.schbul.a007046>

*Meng, H., Schimmelmann, B. G., Koch, E., Bailey, B., Parzer, P., Gunter, M., Mohler, B., Kunz, N., Schulte-Markwort, M., Felder, W., Zollinger, R., Burgin, D., & Resch, F. (2009). Basic symptoms in the general population and in psychotic and non-psychotic psychiatric adolescents. *Schizophrenia Research*, 111, 32–38.

<https://doi.org/10.1016/j.schres.2009.03.001>

Migliavaca, C. B., Stein, C., Colpani, V., Barker, T. H., Ziegelmann, P. K., Munn, Z., Falavigna, M., & Prevalence Estimates Reviews-Systematic Review Methodology Group (PERSyst) (2022). Meta-analysis of prevalence: I² statistic and how to deal with heterogeneity. *Research synthesis methods*, 13(3), 363–367.

<https://doi.org/10.1002/jrsm.1547>

Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich PJ, Stein K, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. *Am J Psychiatry*. 2002;159(5):863–865.

Mirzakhani, H., Singh, F., & Cadenhead, K. S. (2014). Biomarkers in psychosis: An approach to early identification and individualized treatment. *Biomarkers in Medicine*, 8(1), 51–57. <https://doi.org/10.2217/bmm.13.134>

*Møller, P., & Husby, R. (2000). The initial prodrome in schizophrenia: Searching for naturalistic core dimensions of experience and behavior. *Schizophrenia Bulletin*, 26(1), 217–232. <https://doi.org/10.1093/oxfordjournals.schbul.a033442>

Moreno-Küstner, B., Martín, C., & Pastor, L. (2018). Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. *PloS one*, 13(4), e0195687. <https://doi.org/10.1371/journal.pone.0195687>

*Morgan, C., Abdul-Al, R., Lappin, J., Jones, P., Fearon, P., Leese, M., . . . Murray, R. (2006). Clinical and social determinants of duration of untreated psychosis in the ÆSOP first-episode psychosis study. *The British Journal of Psychiatry*, 189(5), 446-452. doi:10.1192/bjp.bp.106.021303

*Mustonen, A., Niemela, S., Nordstrom, T., Murray, G. K., Maki, P., Jaaskelainen, E., & Miettunen, J. (2018). Adolescent cannabis use, baseline prodromal symptoms and the risk of psychosis. *British Journal of Psychiatry*, 212, 227–233. <https://doi.org/10.1192/bjp.2017.52>

*Naqvi, H. A., Hussain, S., Islam, M., & Huma, S. (2014). Early psychosis symptoms. *Journal of the College of Physicians & Surgeons - Pakistan*, 24, 198–202. <https://www.icpsp.pk/archive/2014/Mar2014/13.pdf>

Nieman, D. H., & McGorry, P. D. (2015). Detection and treatment of at-risk mental state for developing a first psychosis: Making up the balance. *The Lancet. Psychiatry*, 2(9), 825–834. [https://doi.org/10.1016/S2215-0366\(15\)00221-7](https://doi.org/10.1016/S2215-0366(15)00221-7)

Page, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., McGuinness, L. A., . . . McKenzie, J. E. (2021). PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. *BMJ (Clinical research ed.)*, 372, n160. <https://doi.org/10.1136/bmj.n160>

*Perkins, D. O., Leserman, J., Jarskog, L. F., Graham, K., Kazmer, J., & Lieberman, J. A. (2000). Characterizing and dating the onset of symptoms in psychotic illness: The Symptom Onset in Schizophrenia (SOS) inventory. *Schizophrenia Research*, 44(1), 1–10. [https://doi.org/10.1016/s0920-9964\(99\)00161-9](https://doi.org/10.1016/s0920-9964(99)00161-9)

*Pierre, K. (2010). *An Exploration of the Harbingers that Differentiate the Schizophrenia Prodrome from a “Bad Patch”*. <https://escholarship.mcgill.ca/concern/theses/x346d463j>

Powers, A. R., Mathys, C., & Corlett, P. R. (2017). Pavlovian conditioning-induced hallucinations result from overweighting of perceptual priors. *Science (New York, N.Y.)*, 357(6351), 596–600. <https://doi.org/10.1126/science.aan3458>

*Rabe-Jablonska, J., Kotlicka-Antczak, M., & Gmitrowicz, A. (2000). Clinical picture and duration of prodromal period of schizophrenia in adolescents. *Archives of Psychiatry and Psychotherapy*, 2, 31–38.

*Renwick, L., Lyne, J., Donoghue, B. O., Owens, L., Doyle, R., Hill, M., McCarthy, E., Pilling, M., O’Callaghan, E., & Clarke, M. (2015). Prodromal symptoms and remission following first episode psychosis. *Schizophrenia Research*, 168, 30–36. <https://doi.org/10.1016/j.schres.2015.07.001>

Riecher-Rössler, A., Butler, S., & Kulkarni, J. (2018). Sex and gender differences in schizophrenic psychoses—a critical review. *Archives of Women's Mental Health*, 21(6), 627–648. <https://doi.org/10.1007/s00737-018-0847-9>

*Röpcke, B., & Eggers, C. (2005). Early-onset schizophrenia: A 15-year follow-up. *European Child & Adolescent Psychiatry*, 14(6), 341–350. <https://doi.org/10.1007/s00787-005-0483-6>

*Russell, A. T. (1994). The clinical presentation of childhood-onset schizophrenia. *Schizophrenia Bulletin*, 20(4), 631–646. <https://doi.org/10.1093/schbul/20.4.631>

Saha, S., Chant, D., Welham, J., & McGrath, J. (2005). A systematic review of the prevalence of schizophrenia. *PLoS medicine*, 2(5), e141. <https://doi.org/10.1371/journal.pmed.0020141>

Salazar de Pablo, G., Estrade Vaz, A., Cutroni, M., Andlauer, O., & Fusar-Poli, P. (2021). Establishing a clinical service to prevent psychosis: What, how and when? Systematic review. *Translational Psychiatry*, 11(1), 43. <https://doi.org/10.1038/s41398-020-01165-x>

Salazar de Pablo, G., Radua, J., Pereira, J., Bonoldi, I., Arienti, V., Besana, F., Soardo, L., Cabras, A., Fortea, L., Catalan, A., Vaquerizo-Serrano, J., Coronelli, F., Kaur, S., Da Silva, J., Shin, J. I., Solmi, M., Brondino, N., Politi, P., McGuire, P., & Fusar-Poli, P. (2021). Probability of transition to psychosis in individuals at clinical high risk: An updated meta-analysis. *JAMA Psychiatry*, *78*(9), 970–978.

<https://doi.org/10.1001/jamapsychiatry.2021.0830>

*Salvatore, P., Khalsa, H. M., Hennen, J., Tohen, M., Yurgelun-Todd, D., Casolari, F., Depanfilis, C., Maggini, C., & Baldessarini, R. J. (2007). Psychopathology factors in first-episode affective and non-affective psychotic disorders. *Journal of Psychiatric Research*, *41*(9), 724–736. <https://doi.org/10.1016/j.jpsychires.2006.04.008>

*Sandeep, M. (2012). *Characterisation of the prodrome to a first episode of psychotic mania: A retrospective study* (1815532270). 10153933, 178

*Schothorst, P. F., Emck, C., & van Engeland, H. (2006). Characteristics of early psychosis. *Comprehensive Psychiatry*, *47*(6), 438–442.

<https://doi.org/10.1016/j.comppsy.2006.03.003>

*Schultze-Lutter, F., Rahman, J., Ruhrmann, S., Michel, C., Schimmelmann, B. G., Maier, W., & Klosterkötter, J. (2015). Duration of unspecific prodromal and clinical high risk states, and early help-seeking in first-admission psychosis patients. *Social Psychiatry & Psychiatric Epidemiology*, *50*, 1831–1841. <https://doi.org/10.1007/s00127-015-1093-3>

*Schultze-Lutter, F., Ruhrmann, S., Berning, J., Maier, W., & Klosterkötter, J. (2010). Basic symptoms and ultrahigh risk criteria: Symptom development in the initial prodromal state. *Schizophrenia Bulletin*, *36*, 182–191.

<https://doi.org/10.1093/schbul/sbn072>

*Shah, J. L., Crawford, A., Mustafa, S. S., Iyer, S. N., Joobar, R., & Malla, A. K. (2017). Is the clinical high-risk state a valid concept? Retrospective examination in a first-episode psychosis sample. *Psychiatric Services*, *68*, 1046–1052.

<https://doi.org/10.1176/appi.ps.201600304>

Shah, J. L., Scott, J., McGorry, P. D., Cross, S. P. M., Keshavan, M. S., Nelson, B., Wood, S. J., Marwaha, S., Yung, A. R., Scott, E. M., Öngür, D., Conus, P., Henry, C.,

Hickie, I. B., & International Working Group on Transdiagnostic Clinical Staging in Youth Mental Health (2020a). Transdiagnostic clinical staging in youth mental health: A first international consensus statement. *World Psychiatry: Official Journal of the World Psychiatric Association (WPA)*, 19(2), 233–242. <https://doi.org/10.1002/wps.20745>

Shah, J.L., Allen, N.B., Avenevoli, S., Correll, C.U., Fisher, H.L., Hickie, I.B., Luna, B., Öngür, D., Yung, A.R. (2020b). A developmentally informed approach to characterizing, staging, and intervening in youth mental health problems. From the population to the clinic. In P.J. Uhlhaas & S.J. Wood (Eds.), *Youth Mental Health: A Paradigm for Prevention and Early Intervention*. Cambridge, MA: The MIT Press.

Shah, J. L., Jones, N., van Os, J., McGorry, P. D., & Gülöksüz, S. (2022). Early intervention service systems for youth mental health: Integrating pluripotentiality, clinical staging, and transdiagnostic lessons from early psychosis. *The Lancet. Psychiatry*, 9(5), 413–422. [https://doi.org/10.1016/S2215-0366\(21\)00467-3](https://doi.org/10.1016/S2215-0366(21)00467-3)

*Shioiri, T., Shinada, K., Kuwabara, H., & Someya, T. (2007). Early prodromal symptoms and diagnoses before first psychotic episode in 219 inpatients with schizophrenia. *Psychiatry and Clinical Neurosciences*, 61(4), 348–354. <https://doi.org/10.1111/j.1440-1819.2007.01685.x>

Simon, A. E., Ferrero, F. P., & Merlo, M. C. G. (2001). Prodromes of first-episode psychosis: How can we challenge neurospecificity. *Comprehensive Psychiatry*, 42(5), 382–392. <https://doi.org/10.1053/comp.2001.26272>

*Skokou, M., Katrivanou, A., Andriopoulos, I., & Gourzis, P. (2012). Sintomatología de las fases activa y prodrómica de la esquizofrenia paranoide de inicio en el joven y de inicio tardío [Active and prodromal phase symptomatology of young-onset and late-onset paranoid schizophrenia]. *Revista de Psiquiatria y Salud Mental*, 5(3), 150–159. <https://doi.org/10.1016/j.rpsm.2012.03.002>

Solmi, M., Radua, J., Olivola, M., Croce, E., Soardo, L., Salazar de Pablo, G., Il Shin, J., Kirkbride, J. B., Jones, P., Kim, J. H., Kim, J. Y., Carvalho, A. F., Seeman, M. V., Correll, C. U., & Fusar-Poli, P. (2022). Age at onset of mental disorders worldwide: Large-scale meta-analysis of 192 epidemiological studies. *Molecular Psychiatry*, 27(1), 281–295. <https://doi.org/10.1038/s41380-021-01161-7>

Spence JR, Stanley DJ (2016) Prediction Interval: What to Expect When You're Expecting ... A Replication. *PLoS ONE* 11(9): e0162874.
<https://doi.org/10.1371/journal.pone.0162874>

*Stepniak, B., Papiol, S., Hammer, C., Ramin, A., Everts, S., Hennig, L., Begemann, M., & Ehrenreich, H. (2014). Accumulated environmental risk determining age at schizophrenia onset: A deep phenotyping-based study. *The Lancet. Psychiatry*, 1, 444–453. [https://doi.org/10.1016/S2215-0366\(14\)70379-7](https://doi.org/10.1016/S2215-0366(14)70379-7)

*Sullivan, H. S. (1932). The relation of onset to outcome in schizophrenia. *Schizophrenia (Dementia Praecox)*. 111–118.

*Tan, H. Y., & Ang, Y. G. (2001). First-episode psychosis in the military: A comparative study of prodromal symptoms. *The Australian and New Zealand journal of psychiatry*, 35(4), 512–519. <https://doi.org/10.1046/j.1440-1614.2001.00912.x>

Teufel, C., Subramaniam, N., Dobler, V., Perez, J., Finnemann, J., Mehta, P. R., Goodyer, I. M., & Fletcher, P. C. (2015). Shift toward prior knowledge confers a perceptual advantage in early psychosis and psychosis-prone healthy individuals. *Proceedings of the National Academy of Sciences of the United States of America*, 112(43), 13401–13406. <https://doi.org/10.1073/pnas.1503916112>

Trovão, N., Prata, J., VonDoellinger, O., Santos, S., Barbosa, M., & Coelho, R. (2019). Peripheral biomarkers for first-episode psychosis-opportunities from the neuroinflammatory hypothesis of schizophrenia. *Psychiatry Investigation*, 16(3), 177–184. <https://doi.org/10.30773/pi.2018.12.19.1>

*Varsamis, J., & Adamson, J. D. (1971). Early schizophrenia. *Canadian Psychiatric Association Journal*, 16(6), 487–497.
<https://journals.sagepub.com/doi/pdf/10.1177/070674377101600604>

Vercammen, A., & Aleman, A. (2010). Semantic expectations can induce false perceptions in hallucination-prone individuals. *Schizophrenia Bulletin*, 36(1), 151–156.
<https://doi.org/10.1093/schbul/sbn063>

Veritas Health Innovation. (n.d.). *Covidence systematic review software*.
www.covidence.org.

Veronese, M., Santangelo, B., Jauhar, S., D'Ambrosio, E., Demjaha, A., Salimbeni, H., Huajie, J., McCrone, P., Turkheimer, F., & Howes, O. (2021). A potential biomarker for treatment stratification in psychosis: Evaluation of an [¹⁸F] FDOPA PET imaging approach. *Neuropsychopharmacology: Official publication of the American College of Neuropsychopharmacology*, 46(6), 1122–1132. <https://doi.org/10.1038/s41386-020-00866-7>

*Woodberry, K. A., Serur, R. A., Hallinan, S. B., Mesholam-Gately, R. I., Giuliano, A. J., Wojcik, J. D., Keshavan, M. S., Frazier, J. A., Goldstein, J. M., Shenton, M. E., McCarley, R. W., & Seidman, L. J. (2014). Frequency and pattern of childhood symptom onset reported by first episode schizophrenia and clinical high risk youth. *Schizophrenia Research*, 158, 45–51. <https://doi.org/10.1016/j.schres.2014.05.017>

Woods, S. W., Powers, A. R., III, Taylor, J. H., Davidson, C. A., Johannesen, J. K., Addington, J., Perkins, D. O., Bearden, C. E., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Seidman, L. J., Tsuang, M. T., Walker, E. F., & McGlashan, T. H. (2018). Lack of Diagnostic Pluripotentiality in Patients at Clinical High Risk for Psychosis: Specificity of Comorbidity Persistence and Search for Pluripotential Subgroups. *Schizophrenia Bulletin*, 44(2), 254–263. <https://doi.org/10.1093/schbul/sbx138>

Worthington, M. A., & Cannon, T. D. (2021). Prediction and prevention in the clinical high-risk for psychosis paradigm: A Review of the current status and recommendations for future directions of inquiry. *Frontiers in Psychiatry*, 12, 770774. <https://doi.org/10.3389/fpsy.2021.770774>

Wu, E. Q., Shi, L., Birnbaum, H., Hudson, T., & Kessler, R. (2006). Annual prevalence of diagnosed schizophrenia in the USA: A claims data analysis approach. *Psychological Medicine*, 36(11), 1535–1540. <https://doi.org/10.1017/S0033291706008191>

Yale University. (2021). *Reference Deduplicator*. [Web app]. <https://library.medicine.yale.edu/reference-deduplicator>

*Yıldızhan, E., Türkcan, A., İnan, S., Erenkuş, Z., Yalçın, Ö., & Erdoğan, A. (2015). İlk Psikoz Atağı: Belirtiler, Tedavi Başlangıcı ve Klinik Yanıt İlişkisi [First Episode Psychosis:

Relationship of Symptoms, Initial Treatment and Clinical Response]. *Turk Psikiyatri Dergisi*, 26(2), 77–86. <https://pubmed.ncbi.nlm.nih.gov/26111283/>

*Yung, A. R., & McGorry, P. D. (1996). The initial prodrome in psychosis: Descriptive and qualitative aspects. *The Australian and New Zealand journal of psychiatry*, 30(5), 587–599. <https://doi.org/10.3109/00048679609062654>

Yung, A., Yung, A. R., Yuen, H. P., McGorry, P. D., Phillips, L. J., Kelly, D., Dell'Olio, M., Francey, S. M., Cosgrave, E. M., Killackey, E., Stanford, C., Godfrey, K., & Buckby, J. (2005). Mapping the onset of psychosis: The comprehensive assessment of at-risk mental states. *Australian and New Zealand Journal of Psychiatry*, 39(11-12), 964-971. <https://doi.org/10.1111/j.1440-1614.2005.01714.x>

SUPPLEMENTARY MATERIAL:

Prospero listing:

David Benrimoh, Abigail Wright, Melissa Funaro, Peter Phalen, Viktor Dlugunovych, Vinod Srihari, Scott Woods, Keith Gallagher, Albert Powers, Maria Ferrara, Jai Shah. A Systematic Review of Prevalence of the Prodrome Preceding First Episode Psychosis. PROSPERO 2021 CRD42021239797 Available from:

https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021239797

The only main change from the listed protocol was the inclusion of proportion meta-analysis and predictive interval; these were added once it was clear sufficient data would be available to support these analyses.

Supplementary Section 1: Supplemental methods and search strategies

The search was intentionally broad and expected to produce many false positives. This was done in order to capture studies which included estimated of prodrome prevalence even if this was not the study's main endpoint.

While studies of patients with solely drug induced psychosis were excluded, we allowed studies in which a subset of the study sample experienced drug induced psychosis, as these subsets were generally a small proportion of the overall study sample, and this allowed the inclusion of several important studies.

We excluded conference abstracts because these do not generally contain sufficient details about methodology required by the objectives of this review.

In our subgroup analyses, we compared the inconsistency and prevalence estimates from studies which included two approaches to measuring prodrome: those which utilized as part of their definition the DSM3 prodrome definition, which is syndromal in nature; and those which were inspired by the IRAOS instrument, which focuses on a more symptom-driven view of the prodrome. The intent was to determine the differences between syndrome and symptom based approaches, and the extent of inconsistency even *within* a family of studies using similar references. Finally, we considered studies which only had patients with schizophrenia spectrum disorders, and compared them to studies which had more heterogeneous populations (e.g. affective psychoses, delusional disorders, substance-induced psychoses).

All Search Strategies:

Ovid MEDLINE(R) ALL <1946 to March 02, 2021>

1	Schizophrenia/ or Psychotic Disorders/ or (psychos?s or psychotic or schizo*).tw,kw.
2	(first admission or first admit* or first episod* or first hospital* or first present* or onset or preced* or pre-episod* or prepsycho* or preepisod* or pre-psycho* or early schiz*).tw,kw.
3	((early or first) adj (psychoses or psychosis or psychotic or schizo*)).tw,kw.
4	2 or 3
5	Prodromal Symptoms/ or (((insidious or acute or nonacute or non acute) adj onset) or prodrom* or "at risk mental state*" or ARMS or clinical high risk or CHR or CHR-P or ultra high risk or UHR or subthreshold psycho* or cognitive symptom* or basic symptom*).tw,kw.
6	1 and 4 and 5

Embase <1974 to 2021 March 02> (Ovid)

1	schizophrenia/ or psychosis/ or (psychos?s or psychotic or schizo*).tw,kw.
---	--

2	(first admission or first admit* or first episod* or first hospital* or first present* or onset or preced* or pre-episod* or prepsycho* or preepisod* or pre-psycho* or early schiz*).tw,kw.
3	((early or first) adj (psychoses or psychosis or psychotic or schizo*)).tw,kw.
4	2 or 3
5	prodromal symptom/ or (((insidious or acute or nonacute or non acute) adj onset) or prodrom* or "at risk mental state*" or ARMS or clinical high risk or CHR or CHR-P or ultra high risk or UHR or subthreshold psycho* or cognitive symptom* or basic symptom*).tw,kw.
6	1 and 4 and 5
7	6 not ((exp animal/ or nonhuman/) not exp human/)

APA PsycInfo/PsycBooks <1806 to February Week 4 2021> (Ovid)

1	Schizophrenia/ or psychosis/ or (psychos?s or psychotic or schizo*).mp.
---	---

2	"Onset (Disorders)"/ or (first admission or first admit* or first episod* or first hospital* or first present* or onset or preced* or pre-episod* or prepsycho* or preepisod* or pre-psycho* or early schiz*).mp.
3	((early or first) adj (psychoses or psychosis or psychotic or schizo*)).mp.
4	2 or 3
5	prodrome/ or (((insidious or acute or nonacute or non acute) adj onset) or prodrom* or "at risk mental state*" or ARMS or clinical high risk or CHR or CHR-P or ultra high risk or UHR or subthreshold psycho* or cognitive symptom* or basic symptom*).mp.
6	1 and 4 and 5
7	6 not (Animals not (Animals and Humans)).mh.

Web of Science Core Collection (Clarivate)

# 4	#3 AND #2 AND #1
# 3	TS=(prodrom* or "at risk mental state*" or ARMS or "clinical high risk" or CHR or "CHR-P" or "ultra high risk" or UHR or "subthreshold psycho*" or "cognitive

	symptom*" or "basic symptom*") OR TS=((insidious or acute or nonacute or non acute) NEAR onset)
# 2	TS=("first admission" or "first admit*" or "first episod*" or "first hospital*" or "first present*" or onset or preced* or "pre-episod*" or prepsycho* or preepisod* or "pre-psycho*" or "early schiz*") OR TS=((early OR first) NEAR/1 (psychoses or psychosis or psychotic or schizo*))
# 1	TS=(psychosis or psychoses or psychotic or schizo*)

Cochrane

#1	(psychosis or psychoses or psychotic or schizo*):ti,ab,kw
#2	("first admission" or "first admit*" or "first episod*" or "first hospital*" or "first present*" or onset or preced* or "pre-episod*" or prepsycho* or preepisod* or "pre-psycho*" or "early schiz*"):ti,ab,kw OR ((early OR first) NEAR/1 (psychoses or psychosis or psychotic or schizo*)):ti,ab,kw
#3	((prodrom* or "at risk mental state*" or ARMS or "clinical high risk" or CHR or "CHR-P" or "ultra high risk" or UHR or "subthreshold psycho*" or "cognitive symptom*" or "basic symptom*") OR TS=((insidious or acute or nonacute or non acute) NEAR onset)):ti,ab,kw

#4	#1 AND #2 AND #3
----	------------------

Supplementary methods: Data Extraction Form

Attempts were made during extraction to determine the recall interval for patients in retrospective studies (e.g. the time between interview and symptom onset) but this could not be extracted reliably from enough studies for us to be confident in using this in an analysis. The extraction form is included in a PDF attachment. Any data fields included in the form which are not included in Table 1 and 2 were excluded because data was systematically missing from studies or because it was decided by the authors not be useful in the context of the objectives of the review. No data was imputed.

Further comments on a potential prospective study

The ideal population for a prospective study aimed at determining and validating a staged prodrome definition would be a set of help-seeking catchment-based samples; to make these samples practical, they could be limited to children, adolescents, and adults up until age 35 (to align with admission criteria for some early intervention services who seek help for *any* mental health reason). The focus on a help-seeking population would likely bias the sample against those with acute onset or no prodromal symptoms; as such a rigorous case-finding process would need to be put in place in each catchment area to identify patients who develop psychosis and who are not already being followed in the prospective study, and general population sampling methods could also be used in order to supplement help-seeking based recruitment. Detailed retrospective data, validated by multiple sources (e.g. family or school report), would also need to be captured from every patient entering the study, to account for symptoms that may have been experienced prior to study entry; however, rigorous training and frequent inter-rater reliability testing will be required to mitigate the effects of recall bias. Another possibility for a patient sampling method would be a multi-country birth cohort, with entry of participants at age 10; further feasibility studies would be required in order to determine if the temporally dense sampling we recommend would be feasible in this type of study.

Supplementary Table 1: Weights and Estimates for All Studies

Study	Sample size	Proportion (%)	95% CI	Weight (%)	
				Fixed	Random
Sullivan et al., 1932	100	22.000	14.330 to 31.392	0.73	2.01
Shioiri et al., 2007	219	29.680	23.714 to 36.206	1.59	2.06
Day et al., 1987	386	33.420	28.727 to 38.369	2.80	2.08
Ropcke et al., 2005	39	35.897	21.204 to 52.820	0.29	1.87
Guloksuz et al., 2020	26	38.462	20.226 to 59.429	0.20	1.78
Huber et al., 1975	502	46.813	42.378 to 51.285	3.64	2.09
Jackson et al., 1996	50	50.000	35.527 to 64.473	0.37	1.92

Chen et al., 2019	3045	51.166	49.374 to 52.956	22.03	2.10
Mustonen et al., 2018	154	52.597	44.403 to 60.690	1.12	2.04
Eggers et al., 2009	57	54.386	40.656 to 67.645	0.42	1.94
Sandeep et al., 2012	51	58.824	44.169 to 72.416	0.38	1.92
Jackson et al., 1995	313	60.064	54.404 to 65.531	2.27	2.07
Maki et al., 2014	23	60.870	38.542 to 80.292	0.17	1.74
Bensi et al., 2011	253	65.217	58.999 to 71.074	1.84	2.07
Coryell et al., 1988	21	66.667	43.032 to 85.412	0.16	1.71
Shah et al., 2017	351	67.806	62.641 to 72.668	2.55	2.08

Compton et al., 2006-2011	109	69.725	60.187 to 78.159	0.80	2.02
Costello et al., 2012	3000	71.000	69.340 to 72.619	21.71	2.10
Chen et al., 2005	131	72.519	64.038 to 79.953	0.95	2.03
Hafner et al., 1995- 2000	232	73.276	67.091 to 78.855	1.69	2.06
Kanahara et al., 2013	156	73.718	66.079 to 80.433	1.14	2.04
Varsamis et al., 1971	44	75.000	59.662 to 86.807	0.33	1.89
Creel et al., 1988	40	75.000	58.804 to 87.309	0.30	1.88
Rabe-Jablonska et al., 2000	150	78.000	70.515 to 84.346	1.09	2.04
Morgan et al., 2006	470	79.362	75.417 to 82.932	3.41	2.09

lida et al., 1995	39	79.487	63.536 to 90.704	0.29	1.87
Renwick et al., 2015	375	80.533	76.158 to 84.419	2.72	2.08
Conus et al., 2007	597	80.570	77.164 to 83.669	4.33	2.09
Stepniak et al., 2014	1011	81.503	78.970 to 83.852	7.32	2.10
Addington et al., 2002	86	84.884	75.539 to 91.698	0.63	1.99
Dominguez-Martinez et al., 2017	40	85.000	70.165 to 94.290	0.30	1.88
Russel et al., 1994	35	85.714	69.743 to 95.194	0.26	1.85
Perkins et al., 2000	35	85.714	69.743 to 95.194	0.26	1.85
Naqvi et al., 2014	93	86.022	77.283 to 92.342	0.68	2.00

Schultze-Lutter et al., 2015	126	86.508	79.279 to 91.940	0.92	2.03
Ferrara et al., 2021	168	88.095	82.214 to 92.574	1.22	2.05
Kohn et al., 2004	82	89.024	80.185 to 94.857	0.60	1.99
Kim et al., 2009	20	90.000	68.302 to 98.765	0.15	1.70
Tan et al., 2001	30	93.333	77.926 to 99.182	0.22	1.81
Schothorst et al., 2006	129	93.798	88.146 to 97.285	0.94	2.03
Woodberry et al., 2014	40	95.000	83.080 to 99.389	0.30	1.88
Meng et al., 2009	87	96.552	90.252 to 99.283	0.64	1.99
Bechdorf et al., 1998	33	96.970	84.241 to 99.923	0.25	1.83

Skokou et al., 2012	87	97.701	91.941 to 99.720	0.64	1.99
Gottlieb et al., 1941	100	100.000	96.378 to 100.000	0.73	2.01
Yung et al., 1996	21	100.000	83.890 to 100.000	0.16	1.71
Moller et al., 2000	19	100.000	82.353 to 100.000	0.14	1.68
Gourzis et al., 2002	100	100.000	96.378 to 100.000	0.73	2.01
Salvatore et al., 2007	377	100.000	99.026 to 100.000	2.73	2.08
Yildizhan et al., 2015	43	100.000	91.779 to 100.000	0.32	1.89
Barajas et al., 2019	79	100.000	95.438 to 100.000	0.58	1.98
Total (fixed effects)	13774	69.557	68.782 to 70.323	100.00	100.00

Total (random effects)	13774	78.266	72.838 to 83.242	100.00	100.00
------------------------	-------	--------	------------------	--------	--------

Analysis by definition, country and publication year


Further analyses were conducted to assess the impact of changing definitions over time and regional definitional traditions on prevalence rates and are presented in the supplementary material. Using the three prodrome definition categories above, we conducted an ANOVA to determine whether the prevalence rates reported were significantly different across groups. ANOVA was also used to determine if broad geographical areas (continents) differed in terms of prodrome prevalence. Correlation analysis was used to determine if year of publication was significantly associated with reported prevalence estimates. As these were secondary analyses, we did not correct for multiple comparisons.

ANOVA demonstrated no significant differences between the three definition groups ($df=2$, $F=0.1$, $p=0.904$). These were also not different using the Q statistic ($Q(2)=0.228$, $p=0.892$) using a meta-analytic approach.

ANOVA testing for differences in reported prevalence rates by region were not significant ($df=4$, $F=0.14$, $p=0.97$), see Supplementary Figure 1a. Using meta-regression, no differences were found (see supplementary Figure 1b); this is reinforced by observing the scatterplot (supplementary Figure 1c)

Correlation analyses examining prevalence rate by year of publication were also nonsignificant (Pearson correlation=0.23, $p=0.104$). Meta-regression did demonstrate significance for year (with later years predicting higher rates) but the model was poor and had an R^2 value of 0; see supplementary figure 2a for model outputs and 2b for scatterplot by year; the relationship observed may simply have been a result of a very low estimate by the oldest study. Visual inspection of the scatterplot does not provide any indication of a meaningful relationship with year. Indeed, when removing the outlier from 1932 with the lowest prevalence rate (22%), the model is no longer significant (see supplementary figures 2c and 2d).

Supplementary Figure 1a: Prodrome Prevalence by Region (mean at the study level)



Supplementary figure 1b: Model Output for Meta-Regression by region (reference region is North America):

Main results for Model 1, Random effects (MM), Z-Distribution, Logit event rate

Set	Covariate	Coefficient	Standard Error	95% Lower	95% Upper	Z-value	2-sided P-value
	Intercept	1.2549	0.2427	0.7792	1.7307	5.17	0.0000
Region	Region: Asia	-0.0963	0.3984	-0.8772	0.6846	-0.24	0.8090
	Region: Europe	0.0056	0.3172	-0.6161	0.6272	0.02	0.9860
	Region: Multiple	-0.3237	0.6873	-1.6709	1.0235	-0.47	0.6377
	Region: Oceania	-0.3740	0.5272	-1.4072	0.6592	-0.71	0.4781

Q=0.80, df=4, p=0.9391

Statistics for Model 1

Test of the model: Simultaneous test that all coefficients (excluding intercept) are zero
Q = 0.80, df = 4, p = 0.9391

Goodness of fit: Test that unexplained variance is zero
Tau² = 0.6810, Tau = 0.8252, I² = 95.66%, Q = 1060.76, df = 46, p = 0.0000


Comparison of Model 1 with the null model

Total between-study variance (intercept only)
Tau² = 0.5609, Tau = 0.7489, I² = 96.13%, Q = 1292.75, df = 50, p = 0.0000

Proportion of total between-study variance explained by Model 1
R² analog = 0.00 (computed value is -0.21)

Number of studies in the analysis 51

Supplementary figure 1c: Scatterplot by region:



Supplementary figure 2a: Model Output for Meta-Regression by year:

Covariate	Coefficient	Standard Error	95% Lower	95% Upper	Z-value	2-sided P-value
Intercept	-32.1683	14.9693	-61.5076	-2.8290	-2.15	0.0316
Year	0.0166	0.0075	0.0020	0.0313	2.23	0.0259

Statistics for Model 1

Test of the model: Simultaneous test that all coefficients (excluding intercept) are zero

Q = 4.96, df = 1, p = 0.0259

Goodness of fit: Test that unexplained variance is zero

Tau² = 0.5900, Tau = 0.7681, I² = 96.07%, Q = 1245.45, df = 49, p = 0.0000

Comparison of Model 1 with the null model

Total between-study variance (intercept only)


Tau² = 0.5609, Tau = 0.7489, I² = 96.13%, Q = 1292.75, df = 50, p = 0.0000

Proportion of total between-study variance explained by Model 1

R² analog = 0.00 (computed value is -0.05)

Number of studies in the analysis 51

Supplementary Figure 2b: Scatterplot by year



Supplementary figure 2c: Model output for metaregression by year, removing the outlier

Main results for Model 1, Random effects (MM), Z-Distribution, Logit event rate

Covariate	Coefficient	Standard Error	95% Lower	95% Upper	Z-value	2-sided P-value
Intercept	-3.5949	20.1800	-43.1471	35.9572	-0.18	0.8586
Year	0.0024	0.0101	-0.0173	0.0221	0.24	0.8109

Statistics for Model 1

Test of the model: Simultaneous test that all coefficients (excluding intercept) are zero

Q = 0.06, df = 1, p = 0.8109

Goodness of fit: Test that unexplained variance is zero

Tau² = 0.5944, Tau = 0.7710, I² = 96.07%, Q = 1220.69, df = 48, p = 0.0000

Comparison of Model 1 with the null model

Total between-study variance (intercept only)


Tau² = 0.5395, Tau = 0.7345, I² = 96.03%, Q = 1233.71, df = 49, p = 0.0000


Proportion of total between-study variance explained by Model 1

R² analog = 0.00 (computed value is -0.10)

Number of studies in the analysis 50

Supplementary Figure 2b: Scatterplot by year, removing the outlier





Sullivan et al., 1932
 Shioiri et al., 2007
 Day et al., 1987
 Ropcke et al., 2005
 Guloksuz et al., 2020
 Huber et al., 1975
 Jackson et al., 1996
 Chen et al., 2019
 Mustonen et al., 2018
 Eggers et al., 2009
 Sandeep et al., 2012
 Jackson et al., 1995
 Maki et al., 2014
 Bensi et al., 2011
 Coryell et al., 1988
 Shah et al., 2017
 Compton et al., 2006-2011
 Costello et al., 2012
 Chen et al., 2005
 Hafner et al., 1995-2000
 Kanahara et al., 2013
 Varsamis et al., 1971
 Creel et al., 1988
 Rabe-Jablonska et al., 2000
 Morgan et al., 2006
 Iida et al., 1995
 Renwick et al., 2015
 Conus et al., 2007
 Stepniak et al., 2014
 Addington et al., 2002
 Dominguez-Martinez et al., 2017
 Russel et al., 1994
 Perkins et al., 2000
 Naqvi et al., 2014
 Schultze-Lutter et al., 2015
 Ferrara et al., 2021
 Kohn et al., 2004
 Kim et al., 2009
 Tan et al., 2001
 Schothorst et al., 2006
 Woodberry et al., 2014
 Meng et al., 2009
 Bechdorf et al., 1998
 Skokou et al., 2012
 Gottlieb et al., 1941
 Yung et al., 1996
 Moller et al., 2000
 Gourzis et al., 2002
 Salvatore et al., 2007
 Yildizhan et al., 2015
 Barajas et al., 2019
 Total (fixed effects)
 Total (random effects)

